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The European Society for Clinical Microbiology and Infectious Diseases, the European Confederation of
Medical Mycology and the European Respiratory Society Joint Clinical Guidelines focus on diagnosis and
management of aspergillosis. Of the numerous recommendations, a few are summarized here. Chest
computed tomography as well as bronchoscopy with bronchoalveolar lavage (BAL) in patients with sus-
picion of pulmonary invasive aspergillosis (IA) are strongly recommended. For diagnosis, direct micro-
scopy, preferably using optical brighteners, histopathology and culture are strongly recommended. Serum
and BAL galactomannan measures are recommended as markers for the diagnosis of IA. PCR should be
considered in conjunction with other diagnostic tests. Pathogen identiﬁcation to species complex level is
strongly recommended for all clinically relevant Aspergillus isolates; antifungal susceptibility testing
should be performed in patients with invasive disease in regions with resistance found in contemporary
surveillance programmes. Isavuconazole and voriconazole are the preferred agents for ﬁrst-line treatment
of pulmonary IA, whereas liposomal amphotericin B ismoderately supported. Combinations of antifungals
as primary treatment options are not recommended. Therapeutic drug monitoring is strongly recom-
mended for patients receiving posaconazole suspension or any form of voriconazole for IA treatment, and
in refractory disease, where a personalized approach considering reversal of predisposing factors,
switching drug class and surgical intervention is also strongly recommended. Primary prophylaxis with
posaconazole is strongly recommended in patients with acutemyelogenous leukaemia or myelodysplastic
syndrome receiving induction chemotherapy. Secondary prophylaxis is strongly recommended in high-
risk patients. We strongly recommend treatment duration based on clinical improvement, degree of
immunosuppression and response on imaging. A.J. Ullmann, Clin Microbiol Infect 2018;24:1
© 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Introduction
This is the third fungal diagnosis and management clinical
guideline published in cooperationwith various European scientiﬁc
societies [1e9]. This part of the guideline regarding invasive and
chronic aspergillosis is a condensation of all the recommendationsmade by the guideline subcommittees and is presented in tables for
easier and faster reading.Moredetails onhow the recommendations
were arrived at are planned in supplementary publications. This
Aspergillus guideline will follow the style of other guidelines by
including diagnostic and therapeutic guidance. Other scientiﬁc
groups have published guidelines on this topic previously and all
A.J. Ullmann et al. / Clinical Microbiology and Infection 24 (2018) e1ee38 e3follow the common goal to provide clinicians with best guidance in
their everyday working environment. Our goal was to provide a
comprehensive European guideline focusing on the life-threatening
diseases caused by Aspergillus spp.Methods
Author panel recruitment and organization was similar to what
was done previously [10]. In brief, experts in the ﬁeld were nomi-
nated by the three societies: European Society for Clinical Microbi-
ology and InfectiousDiseases (ESCMID), the EuropeanConfederation
of Medical Mycology (ECMM) and the European Respiratory Society
(ERS). The total of 53 authorswere grouped into their specialﬁelds of
expertise. Subgroup coordinators were responsible for the ﬁrst draft
of recommendations. Therewere two face-to-facemeetings followed
by numerous electronic exchanges. Some of the ﬁrst recommenda-
tions were presented at ECCMID 2014. This summary was reviewed
and approved by all authors and sent to the ESCMID guideline di-
rector for public review. Then the ﬁnal version was submitted to
Clinical Microbiology and Infection for additional peer review and
subsequent publication. Only the rationale of the chronic pulmonary
aspergillosis (CPA) guideline was published ahead of time [11].
Questions were predeﬁned and modiﬁed where appropriate
and the strength of recommendation and quality of evidence was
slightly modiﬁed (Table 1) [12]. Diagnostic tests are regarded as
interventions.Summary of recommendations
Diagnostic procedures
Early diagnosis of invasive aspergillosis (IA) is a challenge and
should be based on the integration of clinical, radiological and
microbiological data.Table 1
Strength of recommendation and quality of evidence
Strength of
recommendation
Deﬁnition
Grade A Societies strongly support a recommendation for use
Grade B Societies moderately support a recommendation for use
Grade C Societies marginally support a recommendation for use
Grade D Societies support a recommendation against use
Quality of
evidence
Deﬁnition
Level I Evidence from at least one properly* designed
randomized, controlled trial (oriented on the primary
end point of the trial)
Level II Evidence from at least one well-designed clinical trial
(including secondary end points), without
randomization; from cohort or caseecontrolled analytic
studies (preferably from more than one centre); from
multiple time series; or from dramatic results of
uncontrolled experiments
Level III Evidence from opinions of respected authorities, based
on clinical experience, descriptive case studies, or
reports of expert committees
Added index Source of Level II evidence
r Meta-analysis or systematic review of randomized
controlled trials
t Transferred evidence, i.e. results from different patients‘
cohorts, or similar immune-status situation
h Comparator group: historical control
u Uncontrolled trials
a Published abstract presented at an international
symposium or meeting
* Poor quality of planning, inconsistency of results, indirectness of evidence etc.
would lower the Strength of recommendation.Thoracic imaging
In patients at risk for IA with fever of unknown origin or clinical
symptoms of lower respiratory tract infection who remain febrile
despite broad-spectrum antibacterial treatment, thin-section chest
computed tomography (multidetector (MDCT), multislice (MSCT),
spiral CT, high resolution CT) at optimized dose (according to the
ALARA (‘As Low As Reasonably Achievable’) principle) is the im-
aging modality of choice (AII) [13e23]. Pulmonary CT angiography
may be of interest in the early diagnosis of IA by depicting directly
vessel occlusion at the level of a suspicious fungal lesion with a
potential high negative predictive value regarding imaging evalu-
ation [24e26], and is required in case of haemoptysis (AII). In
selected patients where CT is not wanted or not feasible, magnetic
resonance imaging (MRI) of the lungs may represent an alternative
imaging to thin-section MSCT [27e32], positron emission
tomography-CT being of modest interest in the diagnostics of IA
[33,34].
No CT scanning technique is 100% sensitive or speciﬁc for pul-
monary IA [35e37]. Classical CT ﬁndings of angioinvasive aspergil-
losis include macronodule(s) >1 cm, which may be surrounded by a
halo of ground-glass attenuation (halo sign, early phase, inconstant)
[36,38e40], pleural based wedge-shaped areas of consolidation
[41], alveolar consolidations [36,42,43], masses (especially in solid
organ transplant (SOT) recipients) [15,38], internal low attenuation
[44], reverse halo sign [45], cavity or air-crescent sign (delayed
ﬁnding), ground glass opacities and pleural effusion [17,35,46].
Bronchoinvasive forms may appear as tracheal or bronchial wall
thickening, centrilobular nodules with tree in bud appearance [14]
in a patchy distribution, predominant peribronchial areas of
consolidation [47] or bronchopneumonia [46] (Table 2).
Bronchoalveolar lavage and biopsies
Other diagnostic procedures include early bronchoalveolar
lavage (BAL) (AII) [48e54], guided by CT ﬁndings [55,56], and less
frequently CT-guided transthoracic biopsies, video-assisted thor-
acoscopic surgery, open lung biopsies, transbronchial biopsies or
convex endobronchial ultrasound transbronchial needle aspiration,
the latter technique appearing to be a promising procedure in this
setting [28,57e72]. Contraindications to these techniques need to
be considered.
Imaging of other sites
Moreover, according to clinical symptoms, paranasal CT, CT or
MRI of the central nervous system (CNS) as well as abdominal CT
may also be required. In particular, ﬁndings of sinusitis with bone
erosion may be observed, intracranial and/or intraorbital extension
of the disease being best evaluated by MRI [73e75]. In the brain,
due to direct spread from paranasal sinuses or haematogenous
dissemination, meningeal enhancement or empyema, cerebral ab-
scess, mycotic aneurysms as well as haemorrhagic lesions and
rarely stroke may be seen [76e79].
Microscopy and culture
Both microscopy and culture should be attempted on appro-
priate specimens from patients at risk for IA (AII) with a priority for
culture in most cases where insufﬁcient material is available.
Demonstrating tissue invasion by hyphae through microscopic
examination of biopsy or autopsy material provides a diagnosis of
proven invasive fungal infection. However, the sensitivity of mi-
croscopy for IA is 50% at best [80]. Specimens may be examined as a
wet mount preparation with or without the addition of 10%
Table 2
Recommendations for imaging and bronchoalveolar lavage
Population Intention Interventiona SoR QoE Comment Ref.
Neutropenia, fever or clinical
symptoms of pneumonia,
empiric antibiotics failing to
achieve defervescence, e.g.
FUO
To detect pulmonary inﬁltrates Chest CT and thin sectionmulti-
detector CT (MDCT)
A II Dose optimization
recommended
[21,31,35,366]
To identify vessel occlusion Chest angio-CT/pulmonary CT
angiography
B II [24e26]
Haemoptysis To identify vessel erosion Chest angio-CT/pulmonary CT
angiography
A II [367,368]
Any, with inﬁltrate To identify possible underlying
fungal or other infectious
disease
BAL A II [21,49e54]
Any, with inﬁltrate To obtain appropriate
specimens for microscopy,
culture and PCR
CT-guided BAL A III [55,56]
Abbreviations: BAL, bronchoalveolar lavage; CT, computed tomography; FUO, fever of unknown origin; PCR, polymerase chain reaction; QoE, Quality of evidence; SoR,
Strength of recommendation.
a Diagnostic tests are interventions.
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or Blancophor™ have the advantages of increased sensitivity, rapid
turnaround time and broad applicability but are not speciﬁc for
Aspergillus (AII). Gomori's methenamine silver stain (GMS) and
periodic acid-Schiff (PAS) can be applied to histological sections
and smears and should be conducted in all cases in which IA is
considered a possibility (Table 3). Respiratory secretions from pa-
tients with suspected aspergillosis must be processed rapidly for
culture to prevent overgrowth by bacteria and yeasts. To achieve
optimal recovery of Aspergillus from BAL ﬂuid, centrifugation of the
sample is advised with investigation of the sediment (AIII). It is
recommended that cultures of high volume untreated sputum and
BAL should be performed as opposed to culturing small volumes of
digested, liqueﬁed samples [81] (Table 4). Speciﬁc media to support
fungal growth are recommended. Species identiﬁcation to theTable 3
Microscopic examinations
Population Intention Intervention SoR Q
Any To identify fungal elements in
histological sections and stains
Histological examination
Gomori's methenamine silver
stain Periodic acideSchiff
A II
Any To identify fungal elements in
histological sections and stains
Fluorescent dyes: Calcoﬂuor
white™, Uvitex 2B,
Blancophor™
A II
Any To identify fungal elements in
histological sections and stains
Immunohistochemistry
Monoclonal antibody WF-AF-1
or EB-A1
In situ hybridization
B II
Any To identify fungal elements in
fresh clinical specimens (e.g.
BAL)
Application of ﬂuorescent dyes
Calcoﬂuor white™ or Uvitex 2B
or Blancophor™
A II
Abbreviations: BAL, bronchoalveolar lavage; CNS, central nervous system; GMS, Gomori's
Quality of evidence; SoR, Strength of recommendation.complex level should be carried out for clinically relevant isolates
from patients who need antifungal treatment, and for epidemio-
logical purposes (AIII) (Table 5).
Non-culture based assays
Galactomannan (GM) detection in ﬂuids (especially BAL) is more
sensitive than culture for diagnosis of IA. GM is reported as optical
density index (ODI). In serum samples anODI cut-off of 0.5 results in
high sensitivity in haematological patients in the absence of mould-
active prophylaxis (AI) (Table 6). Serial screening for serum GM in
prolonged neutropenia and in allogeneic stem cell transplantation
recipients during the early engraftment phase has a high sensitivity
and negative predictive value for IA (AII) [82]. Serial screening is not
recommended in patients on mould-active prophylaxis [83].oE Comment Ref.
I Histopathology is an essential investigation
Inability to deﬁnitively distinguish other ﬁlamentous fungi
GMS: removes cellular background; more sensitive to
hyphal elements
PAS: advantage of counter stain to check cellular detail
[61,80,369,370]
Not speciﬁc to Aspergillus but high sensitivity and the
micromorphology may provide information on the fungal
class (e.g. Aspergillus: typically dichotomous and septate,
Mucorales: pauci-septate and 90 angle branching, yeast:
budding)
Rapid turnaround time
Broad applicability
May be applied to frozen sections, parafﬁn-embedded
tissue
[371e375]
Have the potential to provide genus- and species-speciﬁc
data
Commercially available monoclonal antibodies
WF-AF-1 is speciﬁc for Aspergillus fumigatus, Aspergillus
ﬂavus, and Aspergillus niger
Time consuming and not broadly available
[371e375]
Essential investigation
Not speciﬁc for Aspergillus species
High sensitivity
Rapid turn-around time
Broad applicability
No species identiﬁcation but the micromorphology may
provide information on the fungal class (e.g. Aspergillus:
typically dichotomous and septate, Mucorales: pauci-
septate and 90 angle branching, yeast: budding)
[61,80,376]
methenamine silver stain; HE, haematoxylin-eosin; PAS, Periodic acideSchiff; QoE,
Table 4
Sample selection and pre-analytical respiratory sample treatment
Population Intention Intervention SoR QoE Comment Ref.
Any To achieve a homogeneous sample of
viscous samples such as sputum
Liquefaction using a
mucolytic agent, e.g.
Pancreatin®, Sputolysin®,
or using sonication and 1,4-
dithiothreitol
A III Essential investigation
High-volume sputum culture (entire sample)
shown to signiﬁcantly increase recovery
[81,377]
Any To achieve optimal recovery of
Aspergillus from BAL by centrifugation
and investigation of the sediment
Centrifugation of BALs or
bronchial aspirates
A III Essential investigation
Isolation of Aspergillus dependent on volume
cultured
[81]
Abbreviations: BAL, bronchoalveolar lavage; PCR, polymerase chain reaction; QoE, Quality of evidence; SoR, Strength of recommendation.
Table 5
Culture and Aspergillus species identiﬁcation
Population Intention Intervention SoR QoE Comment Ref.
Any Primary isolation from deep
sites samples (e.g. biopsies,
blood, CSF)
Culture on SDA, BHI agar, PDA
at 30C and 37C for 72 h
A III Blood inhibits conidiation; BHI can help to recover some
isolates; isolation of several colonies or isolation of the
same fungus from a repeat specimen enhance
signiﬁcance
[81,378,379]
Primary isolation from non-
sterile samples, e.g. sputum,
respiratory aspirates
Culture on SDA, BHI agar, PDA
with gentamicin plus
chloramphenicol at 30C and
37C for 72 h
A III High-volume sputum culture (entire sample) shown to
signiﬁcantly increase recovery; quantitative cultures
are not discriminative for infection or colonization
Identiﬁcation of species
complex
Macroscopic and microscopic
examination from primary
cultures
A II Colony colour, conidium size, shape and septation.
Colour of conidia and conidiophore and conidiogenesis
(tease or tape mounts are preferred); expertise needed
for interpretation
Thermotolerance test (growth at 50C for species
conﬁrmation of A. fumigatus)
Identiﬁcation of species
complex (and species
identiﬁcation of A. fumigatus
speciﬁcally)
Culture on identiﬁcation media
at 25e30C, 37C and 50C (2%
MEA and Czapek-Dox Agar) and
microscopic examination
A II
Identiﬁcation at species level MALDI-TOF MS identiﬁcation B II In-house databases are often used to improve
identiﬁcation rates
[380e383]
Identiﬁcation at species level Sequencing of ITS, b-tubulin
and calmodulin
A III Not necessary in organisms with typical growth, but in
cases of atypical growth
[384,385]
To study outbreaks Microsatellite and CSP analysis C II To study outbreaks (which in general may comprise
more than one genotype)
[386e388]
B II To study colonization patterns [389]
Abbreviations: BHI, braineheart infusion; CSF, cerebrospinal ﬂuid; CSP, cell surface protein; ITS, internal transcribed spacer; MALDI-TOF MS, matrix-assisted laser desorption/
ionization time-of-ﬂight mass spectometry identiﬁcation; MEA, malt extract agar; PDA, potato dextrose agar; QoE, Quality of evidence; SDA, Sabouraud dextrose agar; SoR,
Strength of recommendation.
Table 6
Galactomannan testing in blood samples
Population Intention Intervention SoR QoE Comment Ref.
Patients with prolonged
neutropenia or allogeneic
stem cell transplantation
recipients not on mould-
active prophylaxis
Prospective
screening for IA
GM in blooda A I Highest test accuracy requiring two consecutive samples
with an ODI 0.5 or retesting the same sample
Prospective monitoring should be combined with HRCT and
clinical evaluation
[82,94,390e394]
Draw samples
every 3e4 days
C III
Patients with prolonged
neutropenic or allogeneic
stem cell transplantation
recipients on mould active
prophylaxis
Prospective
screening for IA
GM in blooda D II Low prevalence of IA in this setting with consequently low
PPV of blood GM test
Prophylaxis may have a negative impact on sensitivity of
the test or the low yield may be due to decreased incidence
of IA
[395,396]
Patients with a haematological
malignancy
To diagnose IA GM in blooda Signiﬁcantly lower sensitivity in non-neutropenic patients [319,391,397,398]
 Neutropenic patients A II
 Non-neutropenic patients B II
ICU patients To diagnose IA GM in blooda C II Better performance in neutropenic than in non-neutropenic
patients
[89,399]
Solid organ recipients To diagnose IA GM in blooda C II Low sensitivity, good speciﬁcity
Most data for lung SOT
[319,400,401]
Any other patient To diagnose IA GM in blooda C II Piperacillin/tazobactam may no longer be responsible for
false-positive results according to recent studies
Cross-reactivity in case of histoplasmosis, fusariosis,
talaromycosis (formerly: penicilliosis)
False-positive results reported due to ingestion of ice-pops,
transfusions, antibiotics, Plasmalyt® infusion
[398,402e409]
Cancer patients To monitor
treatment
GM in blooda A II [85,353,410]
Abbreviations: GM, galactomannan; IA, invasive aspergillosis; ICU, intensive care unit; ODI, optical density index; PPV, positive predictive value; QoE, Quality of evidence; SoR,
Strength of recommendation; SOT, solid organ transplantation.
a Serum or plasma.
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Table 7
Galactomannan testing in samples other than blood
Population Intention Intervention SoR QoE Comment Ref.
Any To diagnose pulmonary IA To apply GM test on BAL ﬂuid A II GM in BAL is a good tool to diagnose,
optimal cut-off to positivity 0.5 to 1.0
[86,88,411e414]
Any To diagnose cerebral IA To apply GM test on cerebrospinal ﬂuid B II No validated cut-off [415,416]
Any To detect GM in tissue To apply GM test on lung biopsies B II Using a cut-off 0.5 resulted in a sensitivity of
90 % and a speciﬁcity of 95%; specimens
need to be sliced, precondition for doing so
is that sufﬁcient material is available;
dilution in isotonic saline
[61,417]
Abbreviations: BAL, bronchoalveolar lavage; GM, galactomannan; IA, invasive aspergillosis; QoE, Quality of evidence; SoR, Strength of recommendation.
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neutropenic versus neutropenic patients [84]. Decrease of the ODI
during the ﬁrst 2 weeks of antifungal therapy is a reliable predictor
of a satisfactory response in cancer patients [85]. GM detection in
BAL specimens has an excellent performance with evidence that
ODI of 0.5e1.0 has decreased predictive values compared with re-
sults of >1.0 [86] (AII) (Table 7). The test also has diagnostic value in
patients undergoing lung transplantation or who are in intensive
care [87e89]; a sensitivity of 100% and a speciﬁcity of 90.4% was
deﬁned at cut-off of 1.5 [87].
A constituent of the cell wall of many species and genera of
fungi, (1-3)-b-D-glucan (BDG), is released into body ﬂuids in asso-
ciation with fungal infection. A limited role is given for the exclu-
sive testing of the BDG in diagnosing IA (BII) (Table 8); however, the
combination with GM or PCR improves speciﬁc detection [90].
The Aspergillus lateral ﬂow device assay can be performed on
serum and on BAL samples, but at the time of writing this assay is
not commercially available [91] (Table 9).
Aspergillus PCR has been applied mostly to blood and BAL
ﬂuid. For both sample types, a combination with other bio-
markers increases the likelihood of IA [92,93]. The performance
of serum PCR is not signiﬁcantly different from that of whole
blood [94e97]. Prospective screening of high-risk haematological
patients by a combination of GM and PCR improves the diag-
nostic accuracy and is associated with an earlier diagnosis [98,99]
(Tables 10 and 11).Table 8
b-D-glucan assays
Population Intention Intervention SoR Q
Mixed population: adult ICU,
haematological disorders, SOT
To diagnose IFD Diagnostic assay C I
Screening assays C I
Adult haematological malignancy
and HSCT
To diagnose IFD Diagnostic assay C I
ICUdmixed adult
immunocompromised patients
(haematology, SOT, cancer,
immunosuppressive therapy,
liver failure, HIV)
To diagnose IA Diagnostic assay C I
ICUdmixed adult population: SOT,
liver failure, immunosuppressed
Screening assays C I
Adult haematological malignancy
and HSCT
To diagnose IA Diagnostic assay C I
Screening assays C I
Abbreviations: BDG, b-D-glucan test; GM, galactomannan; HSCT, haematopoietic stem c
fungal disease; NPV, negative predictive value; PPV, positive predictive value; QoE, QualOn hyphal positive biopsy samples molecular detection of fungi
is strongly recommended (AII). If no hyphae are visible the diag-
nostic yield of molecular methods is lower (Table 12). Recom-
mendations for storage of original samples and isolates are given in
Table 13. Antibody detection tests are not supported for the diag-
nosis of IA (CII) (Table 14).
Antifungal susceptibility testing
Resistance to antifungal agents is an increasing problem in
Aspergillus diseases [100e102]. Aspergillus species can be intrinsi-
cally resistant to polyenes and azoles [103], or may acquire resis-
tance following exposure to azole compounds [104]. Acquired
resistance to azoles is mainly found in Aspergillus fumigatus and is
reported globally [100,101,105e108]. Resistance may also develop
through exposure to azole fungicides in the environment
[109e112]. As resistant spores are present in ambient air, patients
may present with azole-resistant Aspergillus disease without pre-
vious azole therapy [113,114]. Individual Aspergillus colonies from a
single specimen may harbour different resistance proﬁles [117],
hence multiple colony testing (up to ﬁve colonies) is recommended
to increase sensitivity for azole-resistance detection (BIII).
In clinical laboratories, species identiﬁcation to complex level is
recommended for all clinically signiﬁcant isolates (BIII). Some
species are intrinsically resistant to either azoles or amphotericin B
(Tables 5, 15e17).oE Comment Ref.
I Five different assays
Overall sensitivity of 77% and speciﬁcity of 85%
Speciﬁcity limits its value in this setting
[90,418]
I Two or more consecutive samples: sensitivity: 65%;
speciﬁcity: 93%
Studies included once to thrice weekly. Varies with
assay and cut-off: Wako assay sensitivity: 40%e97%,
speciﬁcity: 51%e99%
[90,418]
I Overall sensitivity: 50%e70%, speciﬁcity: 91%e99% [193e195,419e424]
I Overall sensitivity: 78%e85%, speciﬁcity: 36%e75%,
NPV: 85%e92%
Speciﬁcity increased at higher cut-off values
[425,426]
II Sensitivity: 91%, speciﬁcity: 58%, PPV: 25%, NPV:
98%.
Positive mean of 5.6 days before positive mould
culture
High false-positive rate in early ICU admission
[427]
I Overall sensitivity: 57%e76%, speciﬁcity: 95%e97% [418,419,425]
I Overall sensitivity: 46%, speciﬁcity: 97%
Conﬁrmation with GM increases speciﬁcity
Data suggest BDG is unsuitable for ruling out
diagnosis of IA
ell transplantation; IA, invasive aspergillosis; ICU, intensive care unit; IFD, invasive
ity of evidence; SoR, Strength of recommendation; SOT, solid organ transplantation.
Table 9
Lateral ﬂow device antigen test for invasive aspergillosis
Population Intention Intervention SoR QoE Comment Ref.
Haematological malignancy
and solid organ transplant
To diagnose IA LFD applied on BAL
samples
B II Retrospective study. Sensitivity and speciﬁcity of BAL LFD tests for
probable IPA were 100% and 81% (PPV 71%, NPV 100%), ﬁve patients
with possible IPA had positive LFD, no proven IA
[428]
Haematopoietic stem cell
transplantation
To diagnose IA LFD applied on
serum samples
B II Prospective screening in 101 patients undergoing allogeneic HSCT [429]
Immunocompromised patients To diagnose IA LFD applied on BAL
samples
B II Retrospective study. Sensitivities for LFD, GM, BDG and PCR were
between 70% and 88%. Combined GM (cut-off >1.0 OD) with LFD
increased the sensitivity to 94%, while combined GM (cut-off >1.0
OD) with PCR resulted in 100% sensitivity (speciﬁcity for probable/
proven IPA 95%e98%).
[430]
Abbreviations: BAL, bronchoalveolar lavage; BDG, b-D-glucan test; GM, galactomannan; HSCT, haematopoietic stem cell transplantation; IA, invasive aspergillosis; IFD,
invasive fungal diseases; LFD, lateral device ﬂow; NPV, negative predictive value; PCR, polymerase chain reaction; PPV, positive predictive value; QoE, Quality of evidence; SoR,
Strength of recommendation.
Table 10
PCR on bronchoalveolar lavage or cerebrospinal ﬂuid
Population Intention Intervention SoR QoE Comment Ref.
Patients undergoing allogeneic stem
cell transplantation recipients not on
mould-active prophylaxis
To diagnose IA BAL PCR B II [431]
Patients with pulmonary inﬁltrates and
haematological malignancies and
prolonged neutropenia
To diagnose IA BAL PCR B II Methodically different in-house assays, better
performance in patients without antifungal
treatment, PCR and galactomannan: increases
speciﬁcity
[353,411,430,432e452]
ICU patients, mixed populations To diagnose IA BAL PCR B II Commercially available Aspergillus PCR assays
with good performance data
[81,88,450,453e455]
Patients with haematological
malignancies
To diagnose CNS
aspergillosis or
meningitis
CSF PCR B II 113 CSF samples from 55 immunocompromised
patients sensitivity 100%, speciﬁcity 93%
(retrospective)
[415,456e459]
Abbreviations: BAL, bronchoalveolar lavage; CNS, central nervous system; CSF, cerebrospinal ﬂuid; IA, invasive aspergillosis; ICU, intensive care unit; QoE, Quality of evidence;
SoR, Strength of recommendation.
Table 11
PCR on whole blood, serum or plasma
Population Intention Intervention SoR QoE Comment Ref.
Patients with
haematological
malignancies
To diagnose IA PCR on blood samples B II Meta-analysis: 16 studies PCR single positive test:
Sensitivity: 88%, speciﬁcity: 75%; PCR two consecutive
positive tests: Sensitivity: 75%, speciﬁcity: 87%
[460]
To diagnose IA PCR on serum samples 97% of protocols detected threshold of 10 genomes/mL
serum volume >0.5 mL, elution volume <100 mL, sensitivity:
86%; speciﬁcity: 94%
[461]
To diagnose IA PCR on whole blood samples First blood PCR assay to be compatible with EAPCRI
recommendations, fever driven: Sensitivity: 92%,
speciﬁcity: 95%, negative PCR result to be used to rule out IA
[462]
Haematopoietic stem
cell transplantation
To diagnose IA Prospective screening PCR on
whole blood samples
B II Combination of serum and whole blood superior [94e97]
To diagnose IA Prospective screening PCR on
blood samples
B II Addition of GM and PCR monitoring provides greater
accuracy, PPV 50%e80%, NPV 80%e90%
[98]
To diagnose IA PCR and GM in BAL A II [393]
Abbreviations: BAL, bronchoalveolar lavage; EAPCRI, European Aspergillus PCR Initiative; GM, galactomannan; IA, invasive aspergillosis; NPV, negative predictive value; PCR,
polymerase chain reaction; PPV, positive predictive value; QoE, Quality of evidence; SoR, Strength of recommendation.
Table 12
Molecular diagnostics on biopsies
Population Intention Intervention SoR QoE Comment Ref.
Biopsy with visible
hyphae
To detect and
specify a fungus
Broad-range PCR A II High sensitivity (>90%) and high speciﬁcity (99%); various
molecular-based techniques available
[61,463]
Biopsy with no
visible hyphae
To detect and
specify a fungus
Broad-range PCR C II Sensitivity (57%) and speciﬁcity (96%); ability to distinguish other
fungi; performance only in addition to other tests
[61,463]
Biopsy with visible
hyphae
To detect and
specify a fungus
Broad-range PCR on
wax-embedded
specimens
A II TaKaRa DEXPAT kit and QIAamp DNA mini kit detected fewer than
10 conidia/sample
[464,465]
Any To detect and
specify a fungus
Fresh tissue
samples
B II Aspergillus PCR performance analysis yielded sensitivity/speciﬁcity
rates of 86%/100% (79 patients, retrospective study)
[58]
Abbreviations: QoE, Quality of evidence; SoR, Strength of recommendation.
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Table 13
Storage of original samples and isolates
Population Intention Intervention SoR QoE Comment Ref.
Any To prevent loss of viability of
Aspergillus in clinical samples,
and to reﬂect the original fungal
content
Clinical samples for
culturedshort-term storage:
4C to prevent loss of viability
and to reﬂect the original fungal
content
A III [98,378]
To prevent degradation of
biomarkers, e.g. GM in serum or
BALs or bronchial washes
Complete assay soon after
delivery to laboratory. Avoid
short-term or long-term
storage of serum at 4C
A I GM in serum degrades with short-term and
long-term storage at 4C; BAL ﬂuid GM ODI
remain stable; testing of pos./neg. serum
and BAL ﬂuid pools showed no decline in
GM index over 11 months at e20C
[61,80,369,370,392]
Short-term maintenance of
Aspergillus isolates
Repeated sub-culture A I Viability maintained for several years by
frequent sub-culture; transfer once a
month; maintain at average ambient room
temperature
[98,378]
Long-term preservation of
Aspergillus isolates
Water storage/storage under
mineral oil/silica gel storage/
freeze-drying freezing (e80C/
ceramic beads/liquid nitrogen)
A I Long-term storagemeans storage periods of
5 years or longer; no further transfers
required during this period
Abbreviations: BAL, bronchoalveolar lavage; GM, galactomannan; ODI, optical density index; QoE, Quality of evidence; SoR, Strength of recommendation.
Table 14
Antibody-based diagnosis of invasive aspergillosis [11]
Population Intention Intervention SoR QoE Comment Ref.
Any To diagnose IA Aspergillus-speciﬁc antibodies by EIA: Serion
(Germany), Omega (France), Bio-Rad (France),
Dynamiker (China)
C II Antibodies take a mean of 11 days to develop
after onset of illness; detectable in 29% to 100%
of patients during course of acute IA
[52,466e472]
Precipitating antibodies by agar gel double diffusion
(Microgen Ltd. UK) or counter-immuno-
electrophoresis
C III Consider false-negative results due to
hypogammaglobulinaemia
[473]
Agglutinating antibodies by indirect
haemagglutination (EliTech/Fumouze, France)
C II [473]
Speciﬁc immunoglobulins to Aspergillus by
ImmunoCap®
C III No reference found
Abbreviations: EIA, enzyme immunoassay; IA, invasive aspergillosis; QoE, Quality of evidence; SoR, Strength of recommendation.
Table 15
Indications for testing for azole resistance in clinical Aspergillus isolates
Population Intention Intervention SoR QoE Comment Ref.
All clinically relevant Aspergillus
isolates (in patient groups or
regions with known azole
resistance)
Identify azole resistance Reference MIC testing A II In situations where rapid
testing is available
[105,111,114,116,300,474e484]
Clinically relevant Aspergillus
isolates in patient groups
with high prevalence of azole
resistance or patients
unresponsive to treatment
Identify isolates with
intrinsic resistance
Species identiﬁcation to
complex level
A III Some species are
intrinsically resistantde.g.
A. calidoustus (azole
resistant) and A. terreus
(AmB resistant)
[103,485]
Clinically relevant A. fumigatus
isolates
Identify azole-resistant
A. fumigatus
Routine azole agar
screening
B III Identiﬁes resistant colonies
that require MIC-testing
[118,486]
All isolates eresistance
surveillance
Determine the local
epidemiology of azole
resistance
Periodical reference MIC
testing of A. fumigatus
complex
A II Test at least 100 isolates [105,111,114,300,477e480,482e484]
Azole-resistant isolates Determine nature and
trends in Cyp51A mutation
distribution
Cyp51A-gene mutation
analysis
A II Test resistant isolates from
surveillance survey
[107]
Abbreviations: AmB, Amphotericin B; MIC, minimum inhibitory concentration; QoE, Quality of evidence; SoR, Strength of recommendation.
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performed in patients with invasive disease with the exception of
azole-naive patients in regions with no resistance found in
contemporary surveillance programmes and regularly for epide-
miological purposes including 100 isolates. This is particularly
important in patients who are unresponsive to antifungal treat-
ment, or in patients who are clinically suspected of having an azole-
resistant pathogen (AIII) (Table 15). If MIC testing is not available,
routine agar screening can be used to detect azole resistance(Table 16) [118]. However, such isolates should be referred to a
mycology reference laboratory for MIC testing. Clinical breakpoints
for interpretation of azole and amphotericin B MICs against
Aspergillus are currently available for the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) microdilution
method but remain undetermined for Clinical & Laboratory Stan-
dards Institute (CLSI) methodology. Accordingly, EUCAST (AII) or
CLSI broth microdilution methods (BII) can be used for determi-
nation of routine MICs for clinical guidance and for epidemiological
Table 16
Azole susceptibility testing: timing, methods, and number colonies
Population Intention Intervention SoR QoE Comment Ref.
Any Conﬁrm or reject azole resistance in
clinical A. fumigatus isolates when
antifungal treatment is considered
Azole agar screening test
followed by reference MIC test
where needed
A III MIC testing as soon as the strain is isolated and
without waiting for species ID
[103,114]
Detect azole-resistant A. fumigatus
genotypes in a single culture
Reference MIC testing of
multiple colonies (up to ﬁve
colonies)
B III Multiple genotypes, i.e. azole-susceptible and
azole-resistant, may be present
[115,487,488]
Routine azole agar screening
(up to ﬁve colonies)
B III One resistant colony can be identiﬁed among
four susceptible samples together as recently
validated
[118,486]
Conﬁrm or reject azole resistance by a
validated method
MIC test using EUCAST method
and EUCAST BPs (S, I, R)
A III Applicable to all Aspergillus spp. Breakpoints
established for most species
[489e491]
MIC test using CLSI method and
CLSI ECVs (wild-type/non-wild-
type)
B III Breakpoints not established [491]
MIC testing of various Aspergillus spp. Etest® C III Conﬁrmation by reference test recommended [492e496]
Abbreivations: MIC, minimum inhibitory concentration; QoE, Quality of evidence; SoR, Strength of recommendation.
Table 17
Azole MIC testing: choice of azole compounds
Population Intention Intervention SoR QoE Comment Ref.
Any To determine susceptibility
to itraconazole
MIC (EUCAST/CLSI) A III In general, a sensitive marker for azole resistance in
Aspergillus; test itraconazole and voriconazole as a
minimum
[490,491,497e501]
Any To determine susceptibility
to voriconazole
MIC (EUCAST/CLSI) A III Resistance/reduced susceptibility to other azole(s) may
accompany that of voriconazole; isolated voriconazole
resistance described related to TR46 mutation
[114,489,491,499e502]
Any To determine susceptibility
to posaconazole
MIC (EUCAST/CLSI) B III Posaconazole resistance without itraconazole resistance not
reported so far; current EUCAST breakpoint will misclassify
approximately 15% susceptible isolates as I/R
[300,481,490,491,499e504]
Any To determine susceptibility
to isavuconazole
MIC (EUCAST/CLSI) A III MIC often similar to voriconazole, but needs testing
separately, if isavuconazole is to be used; lower MIC of
isavuconazole as compared to itraconazole and
voriconazole for A. lentulus and A. udagawae (A. fumigatus
complex) (CLSI)
[490,499,500,502,505e507]
Abbreviations: CLSI, Clinical& Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; MIC, minimum inhibitory concentration;
QoE, Quality of evidence; SoR, Strength of recommendation.
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(AII) should be tested to ensure detection of the voriconazole-
resistance mutation TR46/Y121F/T289A [118]. Posaconazole resis-
tance without itraconazole resistance has not been reported
(Table 17). EUCAST (BIII) or CLSI broth microdilution methods (CIII)
can be used to determine amphotericin B MICs but although a
correlation between MIC and clinical outcome exists for Aspergillus
terreus and Aspergillus ﬂavus it remains to be documented for
A. fumigatus due to the scarcity of resistant isolates (Table 17).
Voriconazole and isavuconazole are recommended for the
treatment of IA due to species showing high amphotericin B MICs
(Table 18). Liposomal amphotericin B or amphotericin B lipid
complex (ABLC) are recommended for species with intrinsic high
azole MICs (Tables 19 and 20). In aspergillosis due to A. fumigatus
speciﬁcally, voriconazole or isavuconazole are recommended if the
isolate is voriconazole-susceptible (EUCAST MIC 1 mg/L) (AI). If
resistant (voriconazole MIC >2 mg/L), liposomal amphotericin B
therapy is recommended (AIIu). It is unknown if patients infected
with A. fumigatus with voriconazole MIC 2 mg/L (intermediate),
respond less well to voriconazole monotherapy. These patients may
have an increased probability of failing voriconazole monotherapy,
and combination therapy with an echinocandin or liposomal
amphotericin B monotherapy should be considered for invasive
disease (AIII) (Table 20). In azole-resistant CPA, liposomal ampho-
tericin B or micafungin can be considered (BII) if surgical inter-
vention is precluded [11]. In settings with environmental azole
resistance, no change to the primary regimen for IA is recom-
mended when resistance rates are <10% (AIII). If azole resistancerates are >10%, ﬁrst-line therapy with voriconazole plus echino-
candin (BIII) or liposomal amphotericin B (BIII) is recommended.
Therapeutic drug monitoring
Patients with IA often have multiple conditions associated with
their underlying disease and its treatment that affects the absorp-
tion, distribution, metabolism and clearance of antifungal medi-
cations [119]. As a result, standardized dosing recommendations for
antifungals used in the prevention or treatment of IA may not
achieve effective or safe drug exposures in all patients. Moreover, a
subset of patients with severe infections or difﬁcult to treat sites
(e.g. CNS) or infections caused by Aspergillus spp. with elevated
MICs may require higher drug exposures. Therapeutic drug moni-
toring (TDM) is often the most direct laboratory approach for
identifying patients at jeopardy for treatment failure or toxicity
because of inadequate or excessive drug exposures, and can be used
to ﬁne-tune antifungal dosing to improve the probability of optimal
outcomes (Table 21).
Itraconazole
For itraconazole, a serum trough of 0.5e4 mg/L (measured by
HPLC) is recommended for prophylaxis (AII (efﬁcacy), BII (safety))
and a trough of 1e4 mg/L is recommended during the treatment of
IA (AII (efﬁcacy), BII (safety)) [120e125]. Itraconazole has an active
metabolite, OH-itraconazole that is present in concentrations
similar to those of the parent itraconazole compound (1:1) when
Table 18
Antifungal regimens in intrinsic resistance
Population Intention Intervention SoR QoE Comment Ref.
Amphotericin B MIC 1 mg/L To cure IA Replace AmBwith azole, if azole
tested susceptible
B II [17,170,515e520]
IA due to A. terreus To cure IA Voriconazole A II Avoid AmB [162,521,522]
Isavuconazole A II
Posaconazole B III
Itraconazole B III
IA due to A. calidoustus To cure IA Lipid formulation of AmB A II Avoid azoles [103,523]
IA due to A. tubingensis (A. niger
complex)
To cure IA Other than azole monotherapy C III Higher azole MIC common, but no data on
clinical impact
[496,524,525]
IA due to A. lentulus
(A. fumigatus complex)
To cure IA Other than azole monotherapy
IA due to A. alliaceus (A. ﬂavus
complex)
To cure IA Other than AmB monotherapy C III Avoid AmB [526]
IA due to A. niger complex To cure IA Other than itraconazole and
isavuconazole
B III Isavuconazole, posaconazole, and voriconazole
MIC in general one dilution higher compared
with A. fumigatus; itraconazole MIC in general
two steps higher; limited clinical data
[496,507]
IA due to A. nidulans To cure IA Voriconazole C III AmB MIC elevated, poor clinical responses in
chronic granulomatous disease
[527,528]
Abbreviations: AmB, amphotericin B; IA, invasive aspergillosis; MIC, minimum inhibitory concentration; QoE, Quality of evidence; SoR, Strength of recommendation.
Table 20
Optimal therapy in documented azole-resistance
Population Intention Intervention SoR QoE Comment Ref.
Isolate with voriconazole
MIC ¼ 2 mg/mL
To cure IA Voriconazole þ echinocandin
combination therapy or L-AmB
monotherapy for IA (as well as for CPA)
A III The probability of voriconazole
treatment failure may be higher than in
voriconazole MIC <2
[529e532]
Isolate with voriconazole MIC
>2 mg/mL
To cure IA L-AmB A IIu [113,114,533]
AmB lipid complex C III No reference found.
Voriconazole & anidulafungin B III [529]
Posaconazole & caspofungin C III Posaconazole not licensed for primary
treatment
[534]
Caspofungin or micafungin C III Patients with contra-indications to AmB
and other azoles
No reference found.
Abbreviations: AmB, Amphotericin B; CPA, chronic pulmonary aspergillosis; IA, invasive aspergillosis; L-AmB, liposomal amphotericin B; QoE, Quality of evidence; SoR,
Strength of recommendation.
Table 19
Amphotericin B susceptibility testing
Population Intention Intervention SoR QoE Comment Ref.
Clinically relevant
isolate
Conﬁrm or reject AmB
resistance when
antifungal treatment is
considered
MIC test C III Acquired resistance to AmB is very rare and
therefore correlation with clinical outcome has not
been documented apart from the poorer outcome
for high MIC species (A. terreus and A. ﬂavus
compared with A. fumigatus).
[508e511]
Clinically relevant
isolate
Interpretation of MIC
(EUCAST)
MIC test using EUCAST
method and EUCAST break
points (S, I, R)
B III MIC break points proposed for A. fumigatus and
A. niger
[490,512,513]
Epidemiological cut-offs established for A. ﬂavus,
A. fumigatus, A. niger and A. terreus
A. terreus is not considered a good target for AmB.
A. ﬂavus may be in vitro resistant
Clinically relevant
isolate
Interpretation of MIC
(CLSI)
MIC test using CLSI method
and CLSI ECVs (wild-type/
non-wild-type)
B III ECVs proposed for A. fumigatus, A. ﬂavus, A. nidulans,
A. niger, A. terreus, A. versicolor. No clinical break
points. A. terreus and A. ﬂavus, e.g. with MIC below
the ECV are not good targets for AmB. No clinical
data that A. fumigatus with MIC 2 will respond to
AmB although classiﬁed as wild-type according to
CLSI ECVs.
[514]
Abbreviations: AmB, amphotericin B; CLSI, Clinical & Laboratory Standards Institute; ECV, epidemiological cut-off value; EUCAST, European Committee on Antimicrobial
Susceptibility Testing; QoE, Quality of evidence; SoR, Strength of recommendation.
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concentrations may be reported separately when samples are
analysed by HPLC or LC/MS/MS, but will be included in the overall
report of ‘itraconazole’ concentrations if samples are analysed by
bioassay [126,127]. Therefore, the target range for itraconazole ishigher when reported by bioassay (i.e. 3e17 mg/L) but may vary by
laboratory depending on the reference standards used. Samples
should be acquired within 5e7 days of starting therapy. Repeat
TDM is recommended the following week to conﬁrm that the pa-
tient remains in the therapeutic range, and repeated thereafter as
Table 21
Therapeutic drug monitoring
Clinical scenarios where antifungal therapeutic
drug monitoring may be indicated
Examples, comments
Populations with increased pharmacokinetic
variability
Impaired gastrointestinal function; hepatic dysfunction; children, elderly patients, obese patients, critically
ill patients
Changing pharmacokinetics Intravenous to oral switch, changing gastrointestinal function, changing hepatic or function, physiological-
instability
Interacting medications Patient receiving medication known to induce cytochrome P450 enzymes especially CYP3A4, antacids,
proton-pump inhibitors (itraconazole capsules, posaconazole suspension), antiretroviral medications.
Patients should have medication records screened using a drug interactions screening database before
starting and stopping antifungals (example: www.fungalpharmacology.org, fungal-druginteractions.org, or
http://www.aspergillus.org.uk/content/antifungal-drug-interactions)
Poor prognosis disease Extensive or bulky infection, lesions contiguous with critical structures, central nervous system infection,
multifocal or disseminated infection
Compliance concerns Important issue with longer-term consolidation therapy or secondary prophylaxis in outpatient setting
Suspected breakthrough infection Therapeutic drug monitoring can establish whether fungal disease progression occurred in the setting of
adequate antifungal exposure
Suspected drug toxicity, especially neurotoxicity
(voriconazole)
Exposure-response relationships are described for other toxicities (e.g. hepatotoxicity), the utility of
therapeutic drug monitoring to prevent their occurrence is less well established
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condition, concomitant medications known to interact, or sus-
pected toxicity (Table 22). Steady-state concentrations can often be
predicted from earlier (non-steady) state samples through phar-
macokinetic models or computerized dosage-assistance. In centres
where these tools are available, sampling before day 5e7 may be
preferable.
Voriconazole
A plasma trough concentration of 1e5.5 mg/L is considered
adequate for most patients receiving voriconazole prophylaxis or
treatment (AII, safety and efﬁcacy) [128e133]. However, a trough of
2e6 mg/L (AII, safety and efﬁcacy) is recommended in patients
treated for severe infections (multifocal or disseminated disease,
CNS infections, infection with pathogen with elevated MICs, e.g. an
MIC of 2mg/L) [130,131]. TDM is strongly recommended in children
due to the much higher rates of drug elimination and potential for
underdosing, especially with the lower voriconazole doses rec-
ommended in the past (AII) [134,135]. Plasma levels should be
monitored between 2-5 days after initiation of therapy, and
repeated the following week to conﬁrm that the patient remains in
the therapeutic range. Repeated monitoring is indicated until
steady-state level in the therapeutic range is conﬁrmed, if there are
changes in the patient's clinical condition, concomitant medica-
tions, or suspected toxicity (Table 23).Table 22
Itraconazole therapeutic drug monitoring
Population Intention Intervention SoR
All patients receiving
itraconazole
treatment for IA
Improve efﬁcacy Measure serum trough level on day
5 of therapy or soon after
A
All patients receiving
itraconazole for
prophylaxis for IA
Improve efﬁcacy Measure serum trough level on day
5 of therapy or soon after
A
Patients receiving
itraconazole
Reduce toxicity Measure serum trough level on day
5 of therapy or soon after
B
Abbreviations: HPLC, high performance liquid chromatography; IA, invasive aspergillosis
Strength of recommendation.Posaconazole
For patients receiving posaconazole suspension, a plasma
trough of >0.7 mg/L is recommended during prophylaxis (BII, ef-
ﬁcacy) [136,137]; and a trough of >1 mg/L is recommended if the
patient is receiving treatment for suspected or documented IA (AII,
efﬁcacy) [138]. Currently, no studies have deﬁned an upper plasma
target that is associated with toxicity, although pharmacokinetic
studies supporting the registration of the new posaconazole tablet
and intravenous formulations with the EMA used a provisional cut-
off of 3.75 mg/L [139e141]. Posaconazole plasma trough levels
should be monitored on day 5 of therapy or soon thereafter, and
repeated as clinically indicated.
For most patients prescribed posaconazole, we recommend
using the newer tablet formulation (or intravenous formulation, if
tablet formulation is contraindicated) rather than the suspension
(AII), as tablets are more likely to consistently achieve target
plasma levels and are less affected by gastrointestinally dependent
drug interactions [139]. Currently, there is limited evidence to
suggest that all patients receiving posaconazole tablets or intra-
venous formulation for prophylaxis require routine TDM; however,
our opinion is that when treating suspected or documented
Aspergillus infections, TDM could still be useful if the pathogen has
elevated MICs, is unresponsive to treatment, or in the event of
unexplained toxicity (BIII). Until further data are available, we
recommend using TDM monitoring strategies and plasma troughQoE Comment Ref.
II Target itraconazole level >1 mg/L to 4 mg/L by
HPLC. Hydroxy-itraconazole metabolite
concentrations generally reported separately by
HPLC or LC/MS/MS methods, but included in
‘itraconazole’ concentration report by bioassay.
Therapeutic range by bioassay may vary by
laboratory but typically fall in the range of (3
e17 mg/L)
[122,127,535e537]
II Target itraconazole level >0.5 mg/L (HPLC) or
>3 mg/L (bioassay)
[124]
II Toxicity was associated with itraconazole levels
>17.1 mg/L by itraconazole bioassay, which
correspond to ~4 mg/L by HPLC
[127]
; LC, liquid chromatography; MS, mass spectrometry; QoE, Quality of evidence; SoR,
Table 23
Voriconazole therapeutic drug monitoring
Population Intention Intervention SoR QoE Comment Ref.
All patients receiving voriconazole
treatment for IA
Improve efﬁcacy, safety and
compliance
Measure plasma trough
level after 2e5 days of
therapy or soon after
A II Target range of 1e5.5 mg/L [128e131,133,538e540]
Repeat plasma trough level B II Repeat during second week of
therapy, additional samples as
clinically indicated and outlined
in the text
[128e131,133,538e540]
All patients receiving voriconazole
prophylaxis for IA
Improve efﬁcacy, safety and
compliance of prophylaxis
Measure serum trough
level after 2e5 days of
therapy or soon after, and
4 days after change of dose
A IIt As above; most studies
investigated voriconazole
treatment rather than
prophylaxis
[132,541,542]
Patients with IA due to Aspergillus
strains of reduced azole
susceptibility MIC 2 mg/mL
Improve efﬁcacy of
treatment for isolates with
MIC 2 mg/mL
Measure serum trough
level after 2 to 5 days of
therapy or soon after and
4 days after change of dose
A II Trough >2 mg/L recommended
on the basis of PK/PD analysis
[131,543]
Abbreviations: IA, invasive aspergillosis; MIC, minimum inhibitory concentration; PK/PD, pharmacokinetic/pharmacodynamic; QoE, Quality of evidence; SoR, Strength of
recommendation.
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formulation (Table 24).
Isavuconazole
Although doseeresponse and plasma concentrationeresponse
relationships for isavuconazole have been reported in animal
models, limited data are currently available to deﬁne a target
therapeutic range or support the need for routine TDM for this
agent [142]. Our opinion is that TDM could still be useful in the
clinical assessment or monitoring of patients receiving isavucona-
zole therapy (CIII) if patients are unresponsive to treatment, have
unexpected toxicity, pharmacokinetic drugedrug interactions, or if
isavuconazole is being used to treat pathogens with elevated MICs
or sanctuary sites such as the CNS. In the absence of well-deﬁned
therapeutic targets, documentation of a plasma trough in the
range of 2e3 mg/L (mean concentration range from phase II/III
clinical studies) after day 5 (including loading doses) suggests
adequate drug exposure (Table 25).
Flucytosine
In rare circumstances, ﬂucytosine may be used in combination
with other antifungals for the treatment of triazole-resistantTable 24
Posaconazole therapeutic drug monitoring
Population Intention Intervention SoR QoE Com
Patients receiving
posaconazole
suspension for
treatment of IA
Improve efﬁcacy,
compliance
Serum trough level on
day 5 of therapy or soon
after
A II Tar
Gas
mo
the
Rep
Pro
and
Patients receiving
posaconazole
suspension for
prophylaxis to
prevent IA
Improve efﬁcacy,
compliance
Serum trough level on
day 5 of therapy or soon
after.
C II Tar
Ade
con
Rep
Patients receiving
posaconazole
Improve safety Measure serum trough
level on day 5 of
therapy or soon after
C III If tr
mo
gas
Pos
stu
form
Pos
ass
Abbreviations: IA, invasive aspergillosis; QoE, Quality of evidence; SoR, Strength of recoAspergillus spp. In this scenario, weekly measurements of peak
serum concentrations 2 h following an oral dose (AII) are needed to
conﬁrm that peak concentrations are 50e100 mg/L to reduce the
risk of toxicity. Trough concentrations required for efﬁcacy are
unknown but a level of 25e50 mg/L is recommended based upon
experience from cryptococcosis [143,144].
Hospital environment
Standards for the hospital environment in immunosuppressed
adults and children require special attention. Patients need to be
segregated from construction or renovation (AIIh), potted plants
(BII), and ﬂowers in wards and in patients' rooms (CIII) [145e150].
Published data support the recommendation to accommodate pa-
tients in special hospital roomswith positive air pressure and HEPA
ﬁlters (BII) or laminar airﬂow (BIIh). However, data were with
historical controls, underpowered, or described by multivariate
analysis describing high-risk situations for IA [151e154]. Protective
masks for patients are proven not to be effective outside the pro-
tected area (CII) [155]. Filters for water supply, especially in
showers, are recommended (BII) [156e160]. No data are available
to support regular environmental air sampling to prevent in-
fections. However, indoor sampling is advisable to monitor ﬁlter
efﬁcacy (BIII) [161,162].ments Ref.
get level >1 mg/L.
troresistant tablet or intravenous formulation preferred for
st patients, consider switch to tablet or intravenous, if no
rapeutic levels with oral suspension
eat determination as clinically appropriate
longed half-life gives similar results for random sampling
true trough samples
[138]
get level >0.7 mg/L
quate tissue concentrations may occur despite serum
centration <0.7 mg/L
eat determination as clinically appropriate
[136,137,544e547]
eatment failure or toxicity suspected, therapeutic drug
nitoring may be indicated in patients receiving
troresistant tablet or intravenous formulation
aconazole exposures between 0.5e3.75 mg/L are well
died and considered safe and effective with all three
ulations
aconazole plasma levels above this exposure range may be
ociated with toxicity
[120,121]
mmendation.
Table 25
Isavuconazole therapeutic drug monitoring
Population Intention Intervention SoR QoE Comment Ref.
All patients receiving
isavuconazole
Improve efﬁcacy safety
and compliance
Measure serum trough
level on day 5 of
therapy or soon after
C III Limited data to support routine TDM but may be
indicated in the setting of treatment failure, drug
interactions, or if toxicity is suspected
The long half-life of isavuconazole (130 h) may
support the use of TDM in some clinical situations to
conﬁrm drug clearance before starting medications
metabolized by CYP3A4, especially chemotherapy
agents
FDA advisory
brieﬁng documents
Abbreviations: FDA, US Food and Drug Administration; QoE, Quality of evidence; SoR, Strength of recommendation; TDM, therapeutic drug monitoring.
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Two strategies are accepted for managing patients with hae-
matological malignancy at risk for IA: (i) the patient receives pri-
mary prophylaxis or (ii) the patient receives no prophylaxis but is
monitored at least twice weekly using biomarkers. The decision
between the two strategies depends on local epidemiology, access
to rapid diagnostics and patient characteristics. Breakthrough
fungal diseases may appear through either symptoms or a disease-
identifying biomarker or imaging result. Fig. 1 depicts a consensus
algorithm for patient management.
Primary prophylaxis
At least three studies describe a number of patients who suc-
cumbed with IA missed before death [163e165]. Although diagnostic
procedureshave improvedsince then, theyarenot satisfactory. For this
reason, patients known to be at high risk for IA may receive primary
prophylaxis, especially patients with profound and prolonged neu-
tropenia or with active graft-versus-host disease (GvHD) (Table 26).
Aspergillosis in haematological malignancy and haematopoietic
stem cell transplantation
In patients treated for haematological diseases, prolonged
severe neutropenia is the most important risk factor for theMinimum diagnosc procedures: CT and microbiolo
CT negave / biomarker negave:
If prophylaxis: Connue prophylaxis, consider TDM, and 
acvely exclude alternave foci (e.g. sinusis)
If no prophylaxis: No anfungals and acvely exclude 
alternave foci (e.g. sinusis)
Deﬁnion of paent populaons:
GM (and PCR) monitoring OR mould-acve prophylaxis
Symptoms (e.g. persistent fever)
CT negave / biomarker posive:
Acvely exclude alternave foci (e.g. sinusis). Treat as 
recommended for targeted treatment, but change anfungal 
class if prophylaxis was given
Fig. 1. Management dudevelopment of IA. T-cell-depleted grafts, glucocorticosteroids
and other immune suppressive drugs have been identiﬁed as
further risk factors for IA in the later course after haematopoietic
stem cell transplantation (HSCT), even in non-neutropenic pa-
tients [166]. In fact, up to two-thirds of patients with IA diag-
nosed after allogeneic HSCT are not neutropenic [167], and the
median time of diagnosis of IA after allogeneic HSCT is 82 days
(range, 3e6542 days) [168].Treatment
Providing a deﬁnite diagnosis of IA is a continuously chal-
lenging endeavour for clinicians. The EORTC/MSG deﬁnitions are
only designed for clinical studies. For clinical decision-making,
these deﬁnitions could have a deleterious outcome as conﬁrma-
tion of a proven or probable diagnosis would delay the start of
therapy [169]. Any patient at risk considered by the responsible
clinician as having IA should receive antifungal therapy (AIII)
(Tables 27 and 28). Physicians should consider switching from
intravenous to oral therapy in stable and pharmacokinetically
reliable patients. Treatment duration depends on clinical response
and on immune reconstitution or recovery from GvHD. Good
partial or complete remission requires no persistent clinical,
including imaging (scarring allowed), or microbiological evidence
of disease. The range of the duration of treatment (3 to >50 weeks)
is huge and the evidence base to support any particulargical work-up (cytology, culture & biomarkers)
CT posive / biomarker negave:
If prophylaxis: Disconnue prophylaxis or consider TDM. 
Treat as recommended for targeted treatment, but change 
anfungal class
If no prophylaxis: Start anfungal therapy for fever-driven 
strategy
Posive GM or PCR
CT posive / biomarker posive:
Treat as recommended for targeted treatment, but change 
anfungal class if prophylaxis was given
ring neutropenia.
Table 26
Primary prophylaxis
Population Intention Intervention SoR QoE Comment Ref.
Haematological malignancies, e.g. AML
with prolonged and profound
neutropenia
Lower
incidence of IA
Posaconazole 200 mg tid suspension or
300 mg tablet qd
A I AML/MDS induction only. TDM
especially with oral suspension.
Tablets more bioavailable, bridging
with posaconazole IV formulation
possible
[548]
L-AmB 12.5 mg 2 /weekly, nebulized,
with undetermined dose of ﬂuconazole
B I AML [549,550]
ABLC 3 mg/kg 3 /weekly C IIh No difference to L-AmB regimen [551]
Micafungin 50 mg qd C IIt [552,553]
L-AmB 10 mg/kg q7d C IIu [554]
L-AmB 50 mg abs q2d C IIu [555]
L-AmB 15 mg/kg q14 d C IIu [556]
Voriconazole C IIt Not better than ﬂuconazole [557]
Itraconazole 400 mg/day, oral solution D II No difference to ﬂuconazole
(n ¼ 195) and more toxicity
[121,558e560]
Acute lymphoblastic leukaemia,
remission induction chemotherapy
Lower
incidence of IA
L-AmB 5 mg/kg biw D I L-AmB more toxic than placebo, no
signiﬁcant reduction in IA rate
[561]
Autologous HSCT or treatment of
haematological malignancies besides
acute leukaemia
Lower
incidence of IA
Any mould active agent D III No reference
found.
Allogeneic HSCT (until neutrophil
recovery)
Lower
incidence of IA
Posaconazole 200 mg tid suspension or
300 mg tablet qd
B IIt Neutropenia duration
approximately identical, TDM
[548]
L-AmB 12.5 mg biw, nebulized, with
ﬂuconazole
B IIt [549]
Voriconazole 200 mg bid C I Not better than ﬂuconazole, TDM [557,562]
Micafungin 50 mg/day C I But no difference in subgroup
analysis for aspergillosis
[552]
Itraconazole 400 mg/day oral solution D I Toxicity issues; TDM [549,560]
Allogeneic HSCT (after neutrophil
recovery and no GvHD)
Any antifungal agent D III No study demonstrated outcome
advantage
Allogeneic HSCT (with moderate to
severe GvHD and/or intensiﬁed
immuno-suppression)
Posaconazole 200 mg tid suspension or
300 mg tablet qd
A I TDM [563]
Voriconazole 200 mg bid C II Not better than ﬂuconazole; TDM [557,562]
Itraconazole 400 mg/day, oral solution C II Toxicity issues; TDM [560]
Micafungin 50 mg/day C III Only few patients with GVHD [552]
Allogeneic HSCT (until neutrophil
recovery)
To reduce IA
attributable
mortality
Posaconazole 200 mg tid suspension or
300 mg tablet qd
B IIt Neutropenia duration
approximately identical; TDM
[548]
Allogeneic HSCT (after neutrophil
recovery, without GvHD)
Any other antifungal D III No study demonstrated outcome
advantage
Allogeneic HSCT (with moderate to
severe GvHD and/or intensiﬁed
immuno-suppression)
Posaconazole 200 mg tid suspension or
300 mg tablet qd
A II Mainly IFD-attributable mortality,
TDM
[563]
Abbreviations: ABLC, amphotericin Belipid complex; AML, acute myeloid leukaemia; bid, twice daily; GvHD, graft-versus-host disease; HSCT, haematopoietic stem cell
transplantation; IFD, invasive fungal disease; L-AmB, liposomal amphotericin B; MDS, myelodysplastic syndrome; qd, once daily; QoE, Quality of evidence; SoR, Strength of
recommendation; TDM, therapeutic drug monitoring; tid, thrice daily.
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enhanced CT or, if applicable, biomarkers) is suggested once anti-
fungal treatment is discontinued.
Additional adjunctive therapy such as the administration of
granulocyte colony-stimulating factor (G-CSF) or G-CSF-primed
granulocyte infusions (data mainly from paediatric populations)
received only a weak supportive recommendation (CIII). In re-
fractory cases, G-CSF (or interferon-g) has immunomodulatory ef-
fects [174e179]. No controlled trials have been performed and only
anecdotal data with small numbers of patients exist. Persistent
neutropenia is related with treatment failure, recovery from neu-
tropenia enhances the efﬁcacy of antifungal agents. A recent
Cochrane review investigating the efﬁcacy of granulocyte trans-
fusions indicated nomortality difference for any kind of infection in
patients with neutropenia [180].
Fever-driven (‘empiric’), and diagnosis-driven (‘pre-emptive’)
therapy
As an alternative to prophylaxis, patients could receive the
classical empirical administration of antifungal agents during fever
refractory to broad-spectrum antibacterial agents. Empirictreatment is deﬁned as a fever-driven treatment approach. Patients
who would qualify for this approach are patients receiving induc-
tion or remission chemotherapy for acute leukaemia or myelo-
dysplastic syndrome or conditioning chemotherapy for HSCT.
Empiric antifungal treatment is expected to reduce morbidity
[181e186] and mortality [187,188] (Table 29). The duration of
empiric antifungal treatment is set by the following rules applied in
randomized clinical trials. If the patient is afebrile and has no active
infection or inﬁltrates, then antifungal therapy can be discontinued
after recovery of leucocyte counts [188e190]. Today, antifungal
stewardship may warrant clinical trials on empiric treatment
duration, but no such trial has been conducted so far.
Pre-emptive treatment is a diagnosis-driven strategy. In most
cases, it is deﬁned by positive GM testing. However, chest CT with
pulmonary inﬁltrates could apply as well. The use of BDG and PCR
testing as alternative biomarkers for GM have considerable merit
[191,192], though BDG is not speciﬁc for Aspergillus disease. In
haematological patients, false-positive BDG often results from
contaminated infusions [193e196]. Very few authors wait for
Aspergillus-associated suggestive radiological signs including
nodule, halo sign, wedge-shaped area of consolidation, ordlate in
the course of invasive aspergillosisdthe air crescent sign, before
Table 27
Targeted therapy of pulmonary diseasedﬁrst line
Population Intention Intervention SoR QoE1 QoE2 QoE3 Comment Ref.
1] Neutropenia (non-
allo HSCT recipients)
2] Allo-HSCT (during
neutropenia)
3] Allo-HSCT (w/o
neutropenia) or
other non-
neutropenic
patients
To increase
response and
survival rate
Isavuconazole 200 mg IV tid day 1e2,
then 200 mg qd oral
A I IIt IIt D III, if mould active azole
prophylaxis fewer adverse
effects than voriconazole
[173,507,564,565]
Voriconazole 2 6 mg/kg IV (oral
400 mg bid) on day 1, then 2e4 mg/kg
IV (oral 200e300 mg bid)
A I IIt IIt C III for start with oral; D III, if
prior mould active azole
prophylaxis; TDM
[170,172,507,566]
L-AmB 3 mg/kg B II IIt IIt [171]
Combination of voriconazole 6/4 mg/kg
bid (after 1 week oral possible (300 mg
bid)) þ anidulafungin 200/100 mg
C I IIt, IIt, No signiﬁcant difference
compared to voriconazole, in
GM-positive (subgroup) better
survival; TDM
[172,566]
Caspofungin 70 mg qd day 1, followed
by 50 mg qd (if body weight <80 kg)
C II II II [567e569]
Itraconazole 200 mg q12 h IV on day 1,
then 200 mg/qd
C III IIt,a IIt,a D III for start with oral, TDM
D III, if mould active azole
prophylaxis
[507,537]
AmB lipid complex (ABLC) 5 mg/kg C III III III [570]
Micafungin 100 mg C III III III [571e573]
AmB colloidal dispersion (ABCD)
4e6 mg/kg
D I IIt IIt [142]
Conventional AmB 1e1.5 mg/kg D I IIt IIt [170]
Other combinations D III III III Efﬁcacy unproven [574]
Life-threatening
haemoptysis
Bridging until
neutrophil
recovery
Arterial embolization, emergency
surgical intervention
B III III III [575]
Abbreviations: allo-HSCT, allogeneic haematopoietic stem cell transplantation; AmB, amphotericin B; bid, twice daily; GM, galactomannan; IA, invasive aspergillosis; IV,
intravenous; qd, once daily; QoE, Quality of evidence; SoR, Strength of recommendation; TDM, therapeutic drug monitoring; tid, thrice daily.
Table 28
Targeted therapy of extrapulmonary diseasedﬁrst line
Population Intention Intervention SoR QoE Comment Ref.
Suspected or proven IA of the central
nervous system
To increase
response and
survival rate
Surgical debridement, if
surgically possible
A IIu [576,577]
Voriconazole A IIu n ¼ 5/5 [170]
n¼ 81, 48 proven cases, 33 probable cases, TDM
recommended targeting trough concentration
of 2e5.5 mg/L
[576]
Posaconazole D III 8 patients documented in studies (5 failures) [578]
Itraconazole D III
Lipid formulations of AmB B III Case collections, animal data [579e581]
cAmB D I Renal toxicity [189,582e584]
Echinocandins D III Insufﬁcient tissue penetration [580]
Patients with clinical suspicion of or
proven invasive sinus aspergillosis
To cure Surgery A III Need to be considered on an individual basis
and decision
Patients with invasive sinus
aspergillosis (all levels of certainty:
suspected through proven)
Local antifungal therapy C III
Voriconazole A IIt n ¼ 8/7, TDM recommended [170,585]
L-AmB A IIt Active against mucormycosis as well since
mixed infections occur or cannot be
differentiated
[171]
Posaconazole, itraconazole,
echinocandins
C III Not well speciﬁed in studies, TDM
recommended for posaconazole and
itraconazole
[586,587]
Abbreviations: AmB, Amphotericin B, cAmB, conventional amphotericin B; L-AmB, liposomal amphotericin B; QoE, Quality of evidence; SoR, Strength of recommendation;
TDM, therapeutic drug monitoring.
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mended in targeted treatment.Adult patients without haematological malignancy
Epidemiology
Approximately 43%e80% of the cases of IA appear in patients
without a haematological malignancy [52,197e200], although
these patients are rarely included in the seminal studies of anti-
fungals [170,171,173]. The proportion of these patients is even
increased when exposed to spore concentrations of >25 CFU/m3 in
hospital air [201e204]. The non-haematological populations at riskfor IA include SOT recipients, patients treated with prolonged high-
dose glucocorticosteroids, or with other immunosuppressants,
patients with advanced AIDS or neoplasia, chronic obstructive
pulmonary disease (COPD), liver failure, liver cirrhosis or inﬂuenza,
as well as critically ill patients requiring admission to intensive care
[52,197e199,205e208]. These patients frequently do not fulﬁl the
EORTC/MSG criteria for invasive aspergillosis [169]. Conﬁrmation of
diagnosis may be delayed, resulting in high mortality rates. At the
same time drugedrug interactions and toxicity can occur more
frequently compared with haematological patients [52]. Physicians
need to be aware of the speciﬁc risk factors, clinical manifestations
andmanagement challenges to improve outcome. In SOT recipients
the average incidence of IA ranges from 0.1% to 11.6% [209,210],
Table 29
Fever-driven (‘empiric’) approach
Population Intention Intervention SoR QoE Comment Ref.
Chemotherapy for
haematological
malignancies or
HSCT, neutropenia
<500/mL 96 h, fever
(>38C), and
parenteral broad
spectrum
antibacterial therapy
96 h (some centres
consider 48 h)
Reduction in the
incidence of IA and/
or related mortality
Caspofungin 70 mg qd day 1, followed
by 50 mg qd (if body weight <80 kg)
A I Caspofungin was associated with a
signiﬁcantly higher rate of survival
than L-AmB (subgroup analysis).
[188]
L-AmB 3 mg/kg B I Less toxicity in comparison to cAmB
but more renal toxicity compared
with echinocandin
[188,189]
Voriconazole 6 mg/kg bid IV (oral
400 mg bid) on day 1, then 4 mg/kg bid
IV (oral 200e300 mg bid)
B II Failed the 10% non-inferiority cut-
off when compared with L-AmB,
but ﬁrst-line for aspergillosis.
Activity of azoles empirical therapy
for persistent fever may be limited
in patients receiving prophylaxis
with an agent of the same class.
TDM
[190]
Itraconazole 200 mg qd iv C II Activity of azoles empirical therapy
for persistent fever may be limited
in patients receiving prophylaxis
with an agent of the same class.
TDM
[588]
ABLC 5 mg/kg qd C I Infusion-related toxicity (fever,
chills, hypoxia)
[589]
ABCD 4 mg/kg C I Same as above [590]
cAmB 0.5e1 mg/kg qd D I Poor tolerance due to extreme
toxicity
[189,342,583,584,588,590]
Micafungin 100 mg qd B II [591]
Fluconazole D IIr No activity against Aspergillus [592]
Abbreviations: ABCD, amphotericin B colloidal dispersion; ABLC, amphotericin B lipid complex; cAmB, conventional amphotericin B; IV, intravenous; L-AmB, liposomal
amphotericin B; QoE, Quality of evidence; SoR, Strength of recommendation; TDM, therapeutic drug monitoring.
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transplant recipients, followed by patients receiving liver (4.7%),
heart (4.0%), pancreas (3.4%) and kidney (1.3%) grafts [209e211].
Half the cases will occur in the ﬁrst 3 months after transplantation,
in patients with post-surgical risk factors. Late aspergillosis is more
common in elderly recipients, and patients with pronounced
immunosuppression due to rejection or post-transplant neoplasia
or chronically impaired graft function [210,212].With the exception
of lung transplantation, in which universal prophylaxis is still
common, antifungal prophylaxis will target SOT recipients with
additional risk factors [211]. Risk factors for early IA in all SOT
recipientsdincluding heart transplantsdcomprise renal failure
requiring replacement therapy, re-intervention, cytomegalovirus
disease, and high environmental exposure to mould spores
[211,213e215]. In liver transplantation, a high model for end-stage
liver disease (MELD) score, transplantation in fulminant hepatic
failure, high intraoperative transfusion needs or re-transplantation
are considered indications for post-surgical prophylaxis [216e224].
In lung transplant recipients, risk factors include previous respi-
ratory tract colonization with Aspergillus, single lung transplant,
CMV disease and acquired hypogammaglobulinaemia [225e227].
In kidney transplantation risk factors include COPD, delayed graft
function, bloodstream infection and acute graft rejection [228] and
a >1.25 mg/kg/day average dose of prednisone [229]. Finally, some
polymorphisms in defence genes have also been suggested to in-
crease risk in transplant recipients [230,231].
The incidence of IA in HIV patients has decreased since the
advent of new antiretroviral therapy (2.2 cases per 10 000/year),
but mortality remains high (38%) [232]. IA typically appears in
patients with low CD4 counts and associated conditions such as
neutropenia, advanced cirrhosis, liver transplantation or gluco-
corticosteroid therapy [233e241]. As in other non-haematological
populations, EORTC/MSG criteria only detect half of the IA cases
diagnosed among HIV-infected patients [232] and in a recent series
of autopsies of AIDS patients, only 12% of the patients with IA had
been diagnosed ante mortem [242] (Table 30).Invasive aspergillosis may affect 0.3% of patients with liver
cirrhosis [243]. Both acute liver failure and advanced cirrhosis,
mainly alcoholic hepatitis treated with glucocorticosteroids, have
been recognized as risk factors for IA [205,244e246]. A low level of
clinical suspicion explains that 53% of the cases of IA in cirrhotic
patients are only recognized post-mortem [247] and that liver dis-
ease is independently associatedwith IA-relatedmortality [199,248].
Invasive aspergillosis has also been described in apparently
immunocompetent patients in a critical condition as a complica-
tion of acute respiratory distress syndrome, COPD, inﬂuenza,
pneumonia, burns, severe bacterial infection, surgery and malnu-
trition. Incidence is 4 to 6/1000 intensive care unit admissions and
the mortality is higher than 70% in most series [245,249e252].
Glucocorticosteroid treatment was the major host factor [253,254]
and as in cirrhotic or HIV-positive patients delayed diagnosis is
common [255,256]. Individuals with COPD requiring glucocorti-
costeroids represent a group with especially high mortality
[249,257,258]. Risk factors include admission to an intensive care
unit, chronic heart failure and antibiotic treatment and, above all,
the cumulative dose of glucocorticosteroids [257].
Pulmonary and CNS aspergillosis predominates in these pop-
ulations, but disseminated disease, fulminant and atypical forms
may occur [203,214,225,251,259e267]. The sensitivity of most
diagnostic methods is lower in non-haematological patients.
Isolation of Aspergillus from respiratory cultures has a much lower
positive predictive value so over-diagnosis has to be prevented
[197,268e272]. Regarding imaging ﬁndings, angioinvasive presen-
tation included in the EORTC/MSG criteria is uncommon in this
setting [273]. Airway invasive radiological presentationwas present
in 37% of heart transplant recipients and was associated with
delayed diagnosis and poorer prognosis [214,274]. In COPD and
HIV-positive patients, the most common radiological presentation
was an alveolar inﬁltrate [273,275,276]. Experience with bio-
markers and PCR is still scarce in these populations, but the com-
bination of at least two different methods appears to be the best
diagnostic approach [277e285] (Table 31).
Table 30
Non-haematological patients at high risk
Population Intention Intervention SoR QoE Ref.
SOT lung with pre-transplantation colonization and Aspergillus in
intraoperative culture OR CMV disease OR higher donor age OR
prolonged ischaemia time OR receiving daclizumab OR bronchial
anastomotic ischaemia OR bronchial stent OR single lung SOT
To identify patients
with high risk of IA
Consider prophylaxis B III [210,226,593] [215,594e596]
SOT lung with repeated acute and chronic rejection B IIt [597,598]
SOT heart with re-operation, CMV infection, haemodialysis, other
episode of IA in the program within 2 months
To identify patients
with high risk of IA
Consider prophylaxis A IIh [204]
SOT heart with airborne Aspergillus spores in ICU A II [203,204]
SOT heart with sirolimus OR tacrolimus OR
hypogammaglobulinaemia
B IIh [212,599]
SOT liver with one of the following characteristics: requirement for
dialysis OR re-transplantation OR fulminant hepatic failure OR
MELD score >30
To identify patients
with high risk of IA
Consider prophylaxis B IIh [210,211,217,224,308,
311,600,601e604]
SOT liver with one of the following characteristics: ICU admission or
corticosteroid requirement previous 2e4 weeks to transplant OR
>15 units of packed red blood cells during transplant surgery OR
reoperation involving the intra-abdominal cavity OR
choledochojejunostomy
C III
SOT kidney with one of the following characteristics: pre-transplant
COPD OR delayed graft function OR post-transplant bloodstream
infection OR acute graft rejection
To identify patients
with high risk of IA
Consider prophylaxis A IIh [228]
COPD with one of the following characteristics: high (systemic)
cumulative glucocorticosteroid dose OR refractory to antibiotic
therapy OR admission to the intensive-care unit
To identify patients
with high risk of IA
Consider prophylaxis A IIt [232,257,605,606]
HIV with CD4 count <100 cells/mL To identify patients
with high risk of IA
Consider prophylaxis A IIh [232]
ICU patients with either COPD OR requiring glucocorticosteroids
therapy
To identify patients
with high risk of IA
Consider prophylaxis A IIh [257,605,606]
ICU patients with either acute liver failure OR burns OR severe
bacterial infection OR malnutrition
B III
ICU or SOT recipients with increased environmental exposure To identify patients
with high risk of IA
Consider prophylaxis A II [203,204,607,608]
Liver insufﬁciency To identify patients
with high risk of IA
Consider prophylaxis B IIh [244,609]
Burn patients with positive fungal cultures To identify patients
with high risk of IA
Consider prophylaxis A IIh [610,611]
Percentage of total body surface area burn injury; length of stay B III [608]
Patient receiving one of the following: tumour necrosis factor-a
blockers, basiliximab, daclizumab, inﬂiximab, etanercept,
alemtuzumab, adalimumab, rituximab, abatacept
To identify
populations at high
risk of IA
Consider prophylaxis C III No reference found
Abbreviations: BAL, bronchoalveolar lavage; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disease; IA, invasive aspergillosis; ICU, intensive care unit; QoE,
Quality of evidence; SoR, Strength of recommendation; SOT, solid organ transplantation.
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Despite no comparative studies of antifungal therapy in non-
haematological patients voriconazole remains the ﬁrst option, as
it has been related to reduced mortality [216,286e288] (Table 32).
Combination therapy is uncommon, although retrospective data
were encouraging in SOT recipients [289]. The risks of drugedrug
interactions and toxicity are very important in these populations
and TDM is advisable [290e295]. In patients with liver insufﬁ-
ciency, liposomal amphotericin B is usually the ﬁrst therapeutic
option. Antifungal resistance is not a common problem despite
prophylaxis [296,297], although some cases have been reported
[298e300]. Finally, immune reconstitution syndrome may occur
after therapy initiation [301].
Most lung recipients receive antifungal prophylaxis. Targeted
prophylaxis is preferred in the remaining SOT with risk factors
[211,213,302e305]. However, signiﬁcant variation in practice has
been noted [221,304,306,307]. To avoid drugedrug interactions and
toxicity, echinocandins or inhaled amphotericin are preferentially
used [308e311], although voriconazole has also demonstrated its
efﬁcacy and safety in this setting [217,220,312e314]. Duration of
prophylaxis is adjusted to the presence of risk factors and, with the
exception of lung recipients, is usually limited to 3e4 weeks [215]
(Table 33).Special considerations in children
Presenting symptoms, distributions and patterns of diseases and
vulnerability to IA are similar between children and adults. How-
ever, differences exist in epidemiology and underlying conditions,
usefulness of newer diagnostic tools, pharmacology of antifungal
agents and evidence from interventional phase III studies. Recom-
mendations for paediatric patients are based on efﬁcacy in phase II
and III trials in adults, the availability of paediatric pharmacokinetic
data, safety data and supportive efﬁcacy data. In addition, regula-
tory approval is considered. Therapeutic drug monitoring is always
recommended when mould-active azoles are used as prophylaxis
or treatment.
Primary antifungal prophylaxis may be indicated in paediatric
patients at ‘high risk’ for developing invasive fungal diseases, and
speciﬁcally IA. An incidence rate of IFDs of 10% is usually consid-
ered as high risk. High-risk populations include children with de
novo or recurrent leukaemia (e.g. acute myeloid leukaemia, acute
lymphoblastic leukaemia depending on treatment protocol), bone
marrow failure syndromes with profound and persistent neu-
tropenia (e.g. myelodysplastic syndrome, very severe aplastic
anaemia), allogeneic HSCT recipients, patients with chronic granu-
lomatous disease and those undergoing lung transplantation. For
patients with haematological disorders, the mould-active oral
Table 31
Diagnosis-driven (‘pre-emptive’) approach in non-haematological patients
Population Intention Intervention SoR QoE Comment Ref.
COPD To diagnose IA Respiratory culture A IIu Isolation of Aspergillus in culture from admitted patients
with COPD represents IA in at least 22% of patients
[257,281,282,399]
COPD To diagnose IA GM BAL B IIu Sensitivity/speciﬁcity of BAL GM >1.0 cut-off is 67%/
96%, at GM >0.5 cut-off is 89%/88%
[281]
Underlying respiratory
disease
To diagnose IA Lateral ﬂow device BAL C II Sensitivity/speciﬁcity 77%/92% (Not commercially
available at the time of writing)
[285]
HIV To diagnose IA Direct microscopy A IIh 50% positive [232]
HIV To diagnose IA GM BAL B IIu 53% positive [232]
HIV To diagnose IA GM serum B IIu 34% positive [232]
HIV To diagnose IA Histology A IIu 75% positive [232]
ICU To diagnose IA BDG serum B IIu Autopsy study, non-haematological
immunocompromised critically ill patients with lower
respiratory tract infection. Using 140 pg/mL cut-off,
sensitivity/speciﬁcity 100%/70%
[425]
ICU To diagnose IA BDG serum B IIu BDG appeared a mean of 6.5 days before Aspergilluswas
grown
[427]
ICU To diagnose IA Respiratory culture B IIu [89,612,613]
ICU To diagnose IA GM BAL C IIu Using cut-off ODI 0.5 sensitivity/speciﬁcity 88%e90%/
87%e100%
[89,612,613]
ICU To diagnose IA SeptiFast® C IIh Sensitivity/speciﬁcity 66%/98%, PPV 93%, NPV 88% [614,615]
ICU, others To diagnose IA BAL ﬂuid samples B IIa Sensitivity, speciﬁcity, and positive and negative
predictive values of 80.0%, 93.3%, 80.0%, and 93.3%
This assay differentiates A. fumigatus and A. terreus,
and detects azole resistance
[280]
Non-haematological To diagnose IA Culture A IIh Very low PPV of Aspergillus spp. culture from respiratory
samples
[197]
Non-haematological To diagnose IA Culture A IIh Sensitivity of BAL higher for non-neutropenic patients [52]
Non-haematological To diagnose IA GM serum C II Using cut-off of 0.5 ng/mL sensitivity/speciﬁcity 60%/
89%
[399]
Non-haematological To diagnose IA MycAssay Aspergillus® C II Sensitivity, speciﬁcity, PPV, and NPV of ﬁrst sample/any
sample were 87%/93%, 87%/82%, 34%/34%, 92%/100%
[278]
SOT, any To diagnose IA Respiratory culture D II Low sensitivity and speciﬁcity [87,282]
SOT, any To diagnose IA GM BAL B II Using cut-off ODI 1.0 sensitivity/speciﬁcity 100%/91% [616]
SOT, any To diagnose IA High-resolution chest
computed tomography
A III Bilateral bronchial wall thickening and centrilobular
opacities, tree-in-bud pattern (65%), ground-glass
opacities and/or bilateral areas of consolidation (23%)
[214,617]
SOT, any To diagnose IA Lateral ﬂow device BAL C II n ¼ 11 SOT [284,428,430]
SOT Heart To diagnose IA Respiratory culture A IIh Overall positive predictive value (PPV) 60%e70%, PPV
88%e100% with respiratory specimens other than
sputum; recovery of A. fumigatus PPV 78%e91%
[271]
SOT Heart To diagnose IA High-resolution
computed tomography
of the thorax
A IIh Provided signiﬁcant additional information in 41%;
positive with a normal chest X-ray in 18%
[274]
SOT Lung To diagnose IA BDG serum C IIu Sensitivity/speciﬁcity 64%, 9%, PPV 14%, NPV 50% [618]
SOT Lung To diagnose IA GM BAL B II Using cut-off ODI 1.5 sensitivity/speciﬁcity 100%/90% [87,88,400,619]
SOT Lung To diagnose IA PCR of respiratory
samples
B II [88]
Abbreviations: BAL, bronchoalveolar lavage; BDG, b-D-glucan; COPD, chronic obstructive pulmonary disease; GM, galactomannan; HIV, human immunodeﬁciency virus; IA,
invasive aspergillosis; ICU, intensive care unit; NPV, negative predictive value; ODI, optical density index; PCR, polymerase chain reaction; PPV, positive predictive value; QoE,
Quality of evidence; SoR, Strength of recommendation; SOT, solid organ transplantation.
Table 32
Treatment in non-haematological patients
Population Intention Intervention SoR QoE Comment Ref.
HIV To treat IA Voriconazole A III Consider drugedrug interactions with antiretroviral drugs. [620]
SOT Heart To treat IA Itraconazole C III 6 patients cured with itraconazole 200e400 mg/day
Erratic absorption and interaction with calcineurin
inhibitors and other agents
[621]
SOT, any To treat IA Voriconazole A III e.g. Herbrecht study 11 SOT; voriconazole increases the
levels of anti-calcineurin immunesuppressors, TDM;
monitor liver function tests especially in liver transplant
recipients.
[170,214,287,333,
600,622e624,625e627]
OT, any To treat IA L-AmB A II [628e630]
SOT, any To treat IA Voriconazole &
caspofungin
B II 40 SOT voriconazole & caspofungin (n ¼ 40) vs
amphotericin B (n ¼ 47). Survival beneﬁt in patients with
A. fumigatus or renal insufﬁciency
[289]
SOT, if voriconazole
contraindicated
To treat IA Caspofungin B III Complete response 83%; response 7/9 monotherapy and 7/
10 combination
[631e634]
Abbreviations: HIV, human immunodeﬁciency virus; IA, invasive aspergillosis; L-AmB, Liposomal amphotericin B; QoE, Quality of evidence; SoR, Strength of recommendation;
SOT, solid organ transplantation; TDM, therapeutic drug monitoring.
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Table 33
Prophylaxis in non-haematological patients
Population Intervention Intention SoR QoE Comment Reference
SOT Lung Universala prophylaxis To prevent IA A I Invasive fungal infection appeared at a median of 35 days [304,315,635]
Targeteda prophylaxis To prevent IA C III [315,595,636]
Inhaled cAmB To prevent IA B IIh 25 mg/day for 4 days, followed by 25 mg/week for 7 weeks. More
adverse events in inhaled deoxycholate versus lipid-based
Breakthrough IA in 7%e10%
[637,638]
Inhaled lipid-based AmB To prevent IA A I More adverse events with inhaled deoxycholate versus lipid-based
but similar efﬁcacy; various possible protocols: 50 mg/day for
4 days, then 50 mg/week for 7 weeks; 50 mg/day for 2 weeks, then
once weekly for 10 weeks; 25 mg thrice weekly between day 1 and
day 60 post SOT and once weekly between day 60 and day 180
[625,637e640]
Voriconazole To prevent IA A III Voriconazole 2200 mg/day more hepatotoxic than itraconazole
2200 mg/day. Usual duration of prophylaxis 3e6months; monitor
liver and skin toxicity
[303,304,315,636,641]
Voriconazole pre-emptive,
if colonized
To prevent IA B IIu Breakthrough IA <2% at 6 months [636]
Voriconazole for 3 months To prevent IA C II No effect of voriconazole on the incidence of IA (45% versus 49%) [303]
SOT Heart Universala prophylaxis with
itraconazole or inhaled
AmB
To prevent IA C I [214,642,643]
Universala prophylaxis with
itraconazole or inhaled
AmB
To prevent IA C II IA rates 5% without prophylaxis, 1.5% with itraconazole 2200 mg,
0% with inhaled AmB
[214,642,643]
Targeteda prophylaxis with
echinocandins
To prevent IA A IIt Prophylaxis in 10% of patients, IA rate reduced from 9% to 2%,
attributable mortality from 6% to 2%; duration dependent of risk
factors persistence
[215]
SOT Liver Targeteda prophylaxis with
lipid AmB
To prevent IA B III IA rate reduced, mortality unaffected [600,644e646]
Targeteda prophylaxis with
echinocandins
To prevent IA A I Standard dosed echinocandins reduced IA rate; duration of
prophylaxis usually 21 days post SOT
[217,308,311,647]
Abbreviations: AmB, Amphotericin B; cAmB, conventional amphotericin B deoxycholate IA, invasive aspergillosis; QoE, Quality of evidence; SoR, Strength of recommendation;
SOT, solid organ transplantation.
a Targeted prophylaxis ¼ only if additional risk factors; universal prophylaxis ¼ to all patients in population.
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itraconazole nor posaconazole are licensed for use in patients
<18 years of age. Due to the lack of paediatric data, recommenda-
tions for lung and high-risk liver transplant patients correspond to
those given for adults [213,315]. Secondary prophylaxis to prevent
recurrence of IA when risk factors are persisting is recommended
with an antifungal targeted at the previous Aspergillus species,
which caused the ﬁrst episode (see below and Table 34).
Diagnostic procedures used in children are not different from
those used in adults but their performance may differ. Suggestive
abnormalities (e.g. halo sign, air crescent sign) on chest CT as
described in adults are less common in children in which non-
speciﬁc masses or inﬁltrates predominate [316e318]. The GM test
on blood and BAL samples have a similar sensitivity and speciﬁcity
proﬁle compared with adults [319e327]. The BDG test is not spe-
ciﬁc for Aspergillus and is not validated in children. Higher baseline
levels are reported in healthy children and therefore the cut-off is
unknown [328e332].
General management principles of IA are consistent with those
in adults and include prompt initiation of antifungal therapy,
control of predisposing conditions (e.g. reduction or discontinu-
ation of glucocorticosteroids in immunosuppressed, administra-
tion of colony-stimulating factors in neutropenic patients), and
surgical interventions on a case-by-case basis using a multidis-
ciplinary approach. Voriconazole is recommended as the ﬁrst-line
agent to treat IA in all children except neonates (AIIt). Liposomal
amphotericin B is ﬁrst choice for neonates (AIII) and may replace
voriconazole as ﬁrst-line treatment in areas or institutions with a
high prevalence of azole-resistant A. fumigatus. Upon diagnosis
of invasive pulmonary aspergillosis, thorough evaluation for
further sites of infection is required and should include the
CNS. The optimal duration of therapy is determined by the reso-
lution of all signs and symptoms and reversal of the underlying
deﬁcit in host defences. For salvage therapy and breakthroughinfections, a switch to a different class of antifungals is recom-
mended [123,132,138,170,171,177,333e341] (Table 35).
If a fever-driven (empiric) strategy is used in at risk paediatric
haematological patients, caspofungin or liposomal amphotericin B
is recommended until resolution of fever and neutropenia
[342e344]. Treatment recommendations for a diagnosis-driven
(pre-emptive) strategy correspond to those made for targeted
treatment [185,186,345,346].
Secondary prophylaxis
Secondary prophylaxis is a treatment strategy to prevent
recurrence of IA during a subsequent risk period of immunosup-
pression. Patients with a history of IA previously successfully
treated with antifungals entering a subsequent risk period of
immunosuppression, e.g. allogeneic HCT (early phase), chemo-
therapy resulting in severe neutropenia (i.e. <500/mL and at least
for 7 days), acute GvHD >I or extensive chronic GvHD, or T-cell-
suppressing therapy, including steroids, are at risk. Agents for
secondary prophylaxis are listed in Table 36.
Treatment of refractory disease
Refractory IA is deﬁned as progression of disease and should be
differentiated from stable disease [349]. Patients with radiological
evidence of progression and persisting elevated GM have a very
high probability of treatment failure resulting in death. Assessment
of response should use composite outcome parameters including
clinical, radiological and mycological criteria. Radiological pro-
gression following or closely preceding neutrophil recovery should
be carefully evaluated and is not necessarily indicative of failure.
Keeping this in mind, assessing the response 2 weeks after treat-
ment initiation generally allows prediction of the response, espe-
cially recognizing oncoming failure [350]. In case of GM-negative
Table 34
Prophylaxis in children at high risk
Population Intention Intervention SoR QoE Comment Ref.
Allogeneic HSCT, pre-engraftment
phase; Allogeneic HSCT, post-
engraftment phase, GvHD and
augmented immunosuppression;
High-risk patients with de novo or
recurrent leukaemia, bone marrow
failure syndromes with prolonged
and profound neutropenia
Prevention
of IA
Itraconazole A/Ba IIt TDM recommended; Approved
indication; not approved EU <18 years
[122,560,648e657]
Posaconazole A IIt TDM recommended; only supportive
paediatric data for 13 years of age
[136,137,338,548,563,658e664]
Voriconazole A IIt Not approved for <2 years; Inference
from efﬁcacy from HSCT trials and
supportive studies; TDM recommended
[130,131,135,541,557,562,665e671]
Liposomal
amphotericin B
B IIt/IIIb Not approved for prophylaxis; Optimal
dose of alternate administration
unknown; alternative if triazoles are
not tolerated/contraindicated
[555,672e677]
Micafungin B IIt/IIIb No deﬁnite evidence (trend only) for
prophylactic efﬁcacy against Aspergillus
spp. Alternative if triazoles are not
tolerated or contraindicated
[552,678e682]
Chronic granulomatous disease patients Prevention
of IA
Itraconazole A II Approved indication; not approved in
the EU for <18 years; TDM
recommended
[122,653e656,683,684]
Posaconazole A III Not EU approved for children
<18 years; TDM recommended; PK and
safety data for children 4 years
[136,137,660e663]
Abbreviations: GvHD, graft-versus-host disease; HSCT, haematopoietic stem cell transplantation; IA, invasive aspergillosis; PK, pharmacokinetics; QoE, Quality of evidence;
SoR, Strength of recommendation; TDM, therapeutic drug monitoring.
a SoR ¼ B for allogeneic HSCT post-engraftment phase, GvHD and augmented immunosuppression.
b QoE ¼ III for allogeneic HSCT post-engraftment phase, GvHD and augmented immunosuppression.
Table 35
Treatment in children
Population Intention Intervention SoR QoE Comment Ref.
Any paediatric
population other
than neonates
Treatment proven/
probable IA
Voriconazole 18 mg/kg/day IV day 1,
followed by 16 mg/kg/day IV or 18 mg/
kg/day PO in two divided dosages (up to
14 years and <50 kg); if > 15 years or
>12 years and >50 kg use adult dosing
recommendations
A IIt Not approved in patients
<2 years; TDM recommended.
[130,131,135,170,333,541,
667e670,600,622,623,685e688]
Any paediatric
population other
than neonates
Treatment proven/
probable IA
L-AmB 3 mg/kg/day B IIt Comparison between two
dosages of L-AmB, no
comparison to voriconazole
[171,675,677,689e692]
Any paediatric
population other
than neonates
Treatment proven/
probable IA
Caspofungin 70 mg/m2 day 1, followed
by 50 mg/m2/day (max. 70 mg/day)
C IIt Study prematurely stopped due
to low accrual
[691,567e569,631,632,693e698]
Neonates Treatment proven/
probable IA
L-AmB 3 mg/kg/day A III [699e702]
Abbreviations: IA, invasive aspergillosis; IV, intravenous; L-AmB, liposomal amphotericin B; PO, per os; QoE, Quality of evidence; SoR, Strength of recommendation; TDM,
therapeutic drug monitoring.
A.J. Ullmann et al. / Clinical Microbiology and Infection 24 (2018) e1ee38e20IA, early assessment of response may be difﬁcult and could require
a longer period of therapy. If failure is ascertained, look for poor
vascular supply (i.e. sinusitis requiring surgical treatment), micro-
biological conﬁrmation is recommended as identiﬁcation of the
fungus at the species level is pivotal. If a viable organism is recov-
ered, susceptibility testing is recommended, especially regarding
azole resistance. On the other hand, azole concentration should be
monitored as well (see sections on resistance and therapeutic drug
monitoring within this guideline) [38,85,349,351e357]. The
choices of antifungal agents in refractory disease are listed in
Table 37.
Chronic pulmonary aspergillosis
Chronic pulmonary aspergillosis is an indolent destructive dis-
ease of the lungs usually complicating other pulmonary conditions
occurring in non- or mildly immunocompromised patients
[358,359]. Its manifestations include chronic cavitary pulmonary
aspergillosis (CCPA), which if left untreatedmay progress to chronic
ﬁbrosing pulmonary aspergillosis, Aspergillus nodule and single
aspergilloma [11,360]. Subacute invasive pulmonary aspergillosis
(previously chronic necrotizing pulmonary aspergillosis) is also acavitating destructive lung disease, usually found in moderately
immunocompromised patients, which progresses more rapidly,
typically over 1 to 3 months. The diagnosis of CPA requires a
combination of characteristics: one or more cavities with or
without a fungal ball present or nodules on thoracic imaging, either
direct evidence of Aspergillus infection (culture or microscopy from
biopsy) or an IgG antibody response to Aspergillus spp. and exclu-
sion of alternative diagnoses (especially mycobacterial infection),
all present for at least 3 months [11,361]. Over 90% of patients have
circulating Aspergillus antibody (precipitins) (AII) [362]. A positive
culture of A. fumigatus respiratory tract secretion (BAL, bronchos-
copy aspiration) is not diagnostic because many different pathol-
ogies are attributable to the fungus, and it may be an airway-
colonizing fungus or a plate contaminant in the laboratory.
If a fungal ball is seen, then only a positive test of Aspergillus IgG
or precipitins conﬁrms pathogenicity. Patients may have CPA and
other infections concurrently (see below).
The distinctive hallmark of CCPA is new and/or expanding
cavities with thick or thin walls in those with chronic lung dis-
ease. An intracavitary fungal ball may be present, often with
pleural thickening and extensive parenchymal destruction and/or
ﬁbrosis. Patients may have CPA and other infections concurrently,
Table 36
Secondary prophylaxis
Population Intention Intervention SoR QoE Comment Ref.
Previous IA and undergoing
allogeneic HSCT or entering
risk period with non-
resectable foci of Aspergillus
disease
To reduce risk
of IA recurrence
Secondary prophylaxis with an
Aspergillus active antifungal proven to
be effective in the actual patient
A II Results compared to historical data, mostly in
allogeneic HSCT setting
[703e708]
Voriconazole A IIh IA: 31/45 patients, 1 year cumulative incidence
of IFD 6.7 ± 3.6%, TDM
[703]
Caspofungin 70 mg day 1, followed by
50 mg/day IV until stable engraftment,
followed by 400 mg itraconazole
suspension PO
B IIh [707]
L-AmB followed by voriconazole C II Fungal infection related mortality 28% despite
lipid-based AmB
[706,709]
Previous IA and with resectable
foci of Aspergillus disease
before entering risk period
To reduce risk
of IA recurrence
Surgical resection following by
secondary prophylaxis
B III Timing and methods of surgery important.
Concomitant administration of appropriate
antifungal compound justiﬁed Indication for
surgical intervention by appropriate specialist.
Interdisciplinary consensus needed
[710e714]
Abbreviations: HSCT, haematopoietic stem cell transplantation; IA, invasive aspergillosis, IFD, invasive fungal disease; L-AmB, liposomal amphotericin B; PO, per os; QoE,
Quality of evidence; SoR, Strength of recommendation; TDM, therapeutic drug monitoring.
Table 37
Antifungal drugs in refractory disease
Population Intention Intervention SoR QoE Comment Ref.
Haematological
patients with
refractory IA
Achieve complete
or partial response,
or stable disease,
improve survival
Switch to another drug class A III
Any combination C III No prospective study demonstrated
superiority of combination therapy over
monotherapy
[715]
Voriconazole A II [333,716,624,717]
L-AmB 3e5 mg/kg B II Majority voted for BII others for AII [676,718,719]
ABLC 5 mg/kg C II [570,719,720,628]
ABCD No longer commercially available [721,722]
Caspofungin 70 mg qd day 1, followed
by 50 mg qd (if body weight <80 kg)
B II Very few data in case of voriconazole/
posaconazole failure
[335,717,723e727,633,728]
Micafungin 75e200 mg qd C II [572,729]
Posaconazole 200 mg qid or 400 mg bid
suspension or 300 mg tablet bid day 1,
followed by 300 mg qd
B II [138,336,730,731]
Itraconazole D III In case of refractoriness to voriconazole
Itraconazole oral forms C II Poor bioavailability [126]
Itraconazole IV formulation Commercially not available everywhere [537,732]
Abbreviations: ABCD, amphotericin B colloidal dispersion; ABLC, amphotericin B lipid complex; bid, twice daily; IV, intravenous; L-AmB, Liposomal amphotericin B;; qd, once
daily; qid, four times daily; QoE, Quality of evidence; SoR, Strength of recommendation; TDM, therapeutic drug monitoring.
Table 38
Chronic pulmonary aspergillosis
Population Intention Intervention SoR QoE Comment Ref.
Cavitary or nodular pulmonary
inﬁltrate in non-
immunocompromised
patients
Diagnosis or
exclusion of CPA
Direct microscopy for hyphae A IIt Positive microscopy is a strong indicator of
infection, not studied in CPA, but in ABPA
[733]
Histology A II In CPA histology distinguishes between CNPA
and CCPA
[734]
Fungal culture (respiratory
secretion)
A III Bacterial culture plates are less sensitive than
fungal culture plates
[269]
Cavitary or nodular pulmonary
inﬁltrate in non-
immunocompromised
patients
Diagnosis or
exclusion of CPA
Aspergillus IgG antibodies A II IgG and precipitins test standardization
incomplete
[362]
CPA patients with progressive
disease
Control of infection Itraconazole: Start 200 mg bid,
adjust with TDM
A II No data to indicate which agent is preferable [362,735]
Voriconazole Start 150e200 mg
bid, adjust with TDM
Voriconazole preferred for CNPA and patients
with fungal balls to minimize risk of resistance
[364,736,737]
Posaconazole
400 mg bid (oral suspension)
300 mg qd (delayed release
tablets)
B II Higher rate of adverse events, if some adverse
events with itraconazole and voriconazole
[738]
Abbreviations: ABPA, allergic bronchopulmonary aspergillosis; bid, twice daily; CCPA, chronic cavitary pulmonary aspergillosis; CNPA, chronic necrotizing pulmonary
aspergillosis; CPA, chronic pulmonary aspergillosis; qd, once daily; QoE, Quality of evidence; SAIA, subacute invasive aspergillosis; SoR, Strength of recommendation; TDM,
therapeutic drug monitoring.
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or tuberculosis and non-tuberculous mycobacterial infection.
Aspergillus nodules, which may be single or multiple, may mimic
malignancy as well as nodules seen in rheumatoid arthritis,
coccidioidomycosis, tuberculosis, non-tuberculous mycobacterial
infection and, rarely, actinomycosis or rheumatoid arthritis.
Typically, Aspergillus nodules appear rounded, some with low
attenuation or cavitation within. Some are spiculated, a common
feature of carcinoma [360].
If technically feasible, single aspergilloma should be surgically
removed, preferably through a video-assisted thoracic surgery
technique with due consideration for risks as recommended
[363]. Long-term oral antifungal therapy is strongly recom-
mended in patients with CCPA, partly to reduce general and
respiratory symptoms [364,365], but also to minimize haemopt-
ysis and prevent lung destruction and ﬁbrosis (AII); itraconazole
or voriconazole are effective for CCPA (AIII) [11]. Oral pos-
aconazole is a potential alternative treatment (BII) [11]. Six
months of therapy is the recommended minimum (AI) [11].
Relapse is common after discontinuation. Intravenous therapy for
CPA is useful in patients who fail or are intolerant of triazoles or
have triazole-resistant A. fumigatus. Prednisolone may be
considered for underlying symptom control only if patients are
adequately treated with antifungals. Mild and moderate hae-
moptysis usually responds to tranexamic acid; severe haemopt-
ysis should be arrested with bronchial artery embolization
(Table 38).
Conclusions
This executive summary is a comprehensive guideline covering
many aspects of Aspergillus diseases. It provides guidance for cli-
nicians on prevention of disease, diagnostic procedures, resistance
issues and treatment of IA as well as CPA. The guideline group in-
tends to provide additional publications supporting the rationale of
the recommendations given.
Finally, the guideline group provides comprehensive tables
explaining various options for speciﬁc situations.
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